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Pancreatic cancer is one of the most lethal type of cancer due to its high
metastasis rate and resistance to chemotherapy. Pancreatic fibrosis is a constant
pathological feature of chronic pancreatitis and the hyperactive stroma
associated with pancreatic cancer. Strong evidence supports an important role of
cyclooxygenase-2 (COX-2) and COX-2 generated prostaglandin E2 (PGE2)
during pancreatic fibrosis. Pancreatic stellate cells (PSC) are the predominant
source of extracellular matrix production (ECM), thus being the key players in
both diseases. Given this background, the primary objective is to delineate the
role of PGE2 on human pancreatic stellate cells (PSC) hyper activation
associated with pancreatic cancer.

This study showed that human PSC cells express COX-2 and synthesize
high levels of PGE2. PGE2 stimulated PSC migration and invasion; expression of
extra cellular matrix (ECM) genes and tissue degrading matrix metallo
vii

proteinases (MMP) genes. I further identified the PGE2 EP receptor responsible
for mediating these effects on PSC. Using genetic and pharmacological
approaches I identified the receptor required for PGE2 mediates PSC hyper
activation. Treating PSC with Specific antagonists against EP1, EP2 and EP4,
demonstrated that blocking EP4 receptor only, resulted in a complete reduction
of PGE2 mediated PSC activation. Furthermore, siRNA mediated silencing of
EP4, but not other EP receptors, blocked the effects of PGE2 on PSC fibrogenic
activity. Further examination of the downstream pathway modulators revealed
that PGE2 stimulation of PSC involved CREB and not AKT pathway.

The regulation of PSC by PGE2 was further investigated at the molecular
level, with a focus on COL1A1. Collagen I deposition by PSC is one of the most
important events in pancreatic cancer. I found that PGE2 regulates PSC through
activation of COL1A1 expression and transcriptional activity. Downstream of
PGE2, silencing of EP4 receptor caused a complete reduction of COL1A1
expression and activity supporting the role of EP4 mediated stimulation of PSC.
Taken together, this data indicate that PGE2 regulates PSC via EP4 and suggest
that EP4 can be a better therapeutic target for pancreatic cancer to reduce the
extensive stromal reaction, possibly in combination with chemotherapeutic drugs
can further kill pancreatic cancer cells.
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CHAPTER ONE: INTRODUCTION
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INTRODUCTION TO THE PANCREAS
A brief overview of the development, anatomy, function and histology of
the pancreas is discussed below. For a more thorough description please refer to
references 1-3.(1)

Anatomy and physiology
The human digestive system is composed of the salivary glands, the liver
and the pancreas. The pancreas is an elongated organ is situated in the center of
the abdomen, behind the stomach. The pancreas is composed of a head, neck,
body and tail. The head of the pancreas is the widest part and it lies in the
duodenum while the tapered left side of the pancreas referred to as the body
ends near the spleen. It is surrounded by numerous structures and important
blood vessels.
In humans, the pancreas weighs on average 80 g and is 15 to 20 cm long (1).
During embryogenesis, the dorsal and ventral buds join to form the pancreas.
The duct that forms from the duodenum becomes the duct of Santorini, whereas
the duct forms from the hepatic diverticulum and gives rise to the duct of
Wirsung. The duct of Wirsung collects pancreatic juice and empties it in the
duodenum. With gut rotation, the ventral bud becomes the pancreatic head and
fuses with the dorsal bud, which becomes the body and the tail of the pancreas.
The ducts of both buds fuse together and drain in the pancreatic head where the
2

duct of Wirsung becomes the main pancreatic duct. Enzymes needed for the
digestion of carbohydrates, fat and proteins continuously flow through the ducts.
The ducts fail to fuse in a small percentage of patients which results in mal
function of the pancreas.

Function and histology
The pancreas is composed of two glands: The exocrine gland and the
endocrine gland. In adults, most of the activity of the pancreas is dedicated to
the exocrine gland. The exocrine pancreas and salivary glands share structural
similarities and is controlled by both hormonal and neural s signals. The exocrine
component of the pancreas is composed of acinar cells, which makes up most of
the exocrine pancreas. When the acinar cell is stimulated, it releases the
enzymatic component of the pancreatic juice from the zymogen granules into the
lumen of the acinus where it mixes with the secretions of the centroacinar cells.
As the name indicates the centroacinar cell is the cell that is in the center of the
acinus cell and is part of the ductal system. Under the microscope, the acinar
cells look like blind ended tubules surrounded by polygonal acinar cells, which
resembles a cluster of grapes, hence the name acinar cells which means grape
in latin. The tiny ducts that drain the acini are called intercalated ducts. The
intercalated ducts empty into larger intralobular ducts which in turn drain into an
extralobular duct that empties into larger ducts and then into a main large duct
that drains the pancreas and enters the duodenum. During this trajectory, the
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pancreatic juice accumulates water, chloride and bicarbonates that are secreted
by the duct cells to help neutralize the pH of the duodenal content (2). Each day
the pancreas secretes 1L, more than 10 times its weight of pancreatic fluids. (3)
These secretions contain amylases, proteases and lipases which aid in the
digestion process of carbohydrates, proteins and fats.
The endocrine cells of the pancreas form islets in the parenchyma called
the Islets of Langerhans. There are five types of cells in the Islets of
Langerhans; about 75% of the cells in each islet are insulin producing beta cells.
The remaining 25% of cells consists of alpha, delta and F cells which secrete
glucagon, somatostatin and pancreatic polypeptide and are located at the
periphery of each islet. The hormones secreted by these cells are important in
glucose homeostasis and GI functions such as bile secretion and nutrient storage
(4).

PANCREATIC DUCTAL ADENOCARCINOMA
Epidemiology
Pancreatic ductal adenocarcinoma (PDAC) is the most occurring type of
pancreatic cancer and it affects the exocrine cells of the pancreas. Less than 1%
of pancreatic tumors occur in the endocrine system (5). PDAC is now the fourth
leading cause of cancer related death in the United States although it is ranked
as 10th in the list of most occurring cancers (6). For the year 2010, it is estimated
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that more than 43,000 individuals would have been diagnosed with pancreatic
cancer and 36,800 have died from the disease (6).
Pancreatic cancer is a disease of old individuals. Based on the SEER
cancer statistics, only 13% of individuals are diagnosed before the age of 60 and
more than 50% of the patients are 75 years old and older at the time of
diagnosis(3). Men are 30% more likely to develop pancreatic cancer than
women. Blacks and Jewish people have a higher incidence of pancreatic cancer
compared to Caucasians (7). At the molecular levels, blacks have more frequent
k-ras mutations than Caucasians and Chinese people have a different
expression of Ki-ras and p53 than Caucasians (8).
There are many genetic and environmental risk factors for pancreatic
cancer. Smoking is the strongest environmental factor for pancreatic cancer.
Carcinogens from cigarette smoking enter the bloodstream and reach the
pancreas after leaving the lungs. There is a strong correlation between smoking
and pancreatic cancer(9). Studies show that the risk of pancreatic cancer
increases by two folds in individuals that smoke compared to non smokers (10,
11). An Important risk factor for pancreatic cancer is the diet. Dietary factors can
either increase or decrease the risk of pancreatic cancer. Studies have linked
increased caloric intake and obesity to increased risk of pancreatic cancer. On
the other hand, increased intake of fruits and vegetables reduce the risk (12, 13).
The lack of physical activity has also been reported as a risk factor for pancreatic
cancer (14). Alcohol is a major risk for chronic pancreatitis however studies have
failed to link alcohol consumption to pancreatic cancer. One of the problems
5

trying to link pancreatic cancer to dietary intake and environmental factors is due
to the rapid progression of the disease and the lack of methods for early
detection. Most studies are case control studies and at the time of diagnosis, the
patients are in an advanced stage of the tumor that unable them to respond to
changes in the diet usually incorporated early on as a chemo preventive
measure. However, studies have shown a strong correlation between
preexisting conditions and the risk for pancreatic cancer (15, 16). Alcoholic and
non alcoholic pancreatitis results in an increase of up to 20 folds for pancreatic
cancer. For tropical and hereditary that develops early on the risk for pancreatic
cancer is much higher, up to 40% for patients with hereditary pancreatitis. It is
not clear whether diabetes is a risk for pancreatic cancer since it can be one of
the earlier symptoms of the disease, however many studies have shown that
diabetics have a 2 fold increased chance of developing pancreatic cancer (17).
Mutations in genes such as BRCA1 (18), BRCA2 (19, 20),
p16/CDKN2A(21) and others (20, 22) that are commonly altered in many
cancers, are associated with an increased risk for developing pancreatic cancer .
The most important genetic alteration is that of BRCA2 which is found in up to
10% of patients with sporadic pancreatic cancer and up to 20% of patients with a
family history (23). Most diseases that increase the risk of pancreatic cancer are
autosomally dominant inherited, however, autosomal recessive diseases such as
ataxia-telangiectasia (24), fanconi anemia (25) and cystic fibrosis (26, 27) have
been reported to be linked to the disease.
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Detection and diagnosis of pancreatic cancer
Pancreatic cancer is called “the silent disease” and one of the major
reasons why pancreatic cancer survival is low, is because the symptoms don’t
start to appear until more advances and incurable stages. Most patients show
sudden weight loss. Jaundice is also seen in a number of patients, when the
tumor blocks the bile duct and prevents bile passing to the digestive system,
usually these patients have a better prognosis because the tumor is located at
the head of the pancreas and is resectable. However, tumors that develop at the
tail of the pancreas are usually harder to detect and are asymptomatic therefore
patients have a lower survival rate (28). The most common symptom reported in
around 80% of patients with locally advanced pancreatic cancer is epigastric pain
when eating or lying down. As with other types of cancers, nausea, loss of
appetite and fatigue are reported. Even though it is uncertain whether diabetes is
directly correlated with pancreatic cancer, patients over 50 years old that develop
diabetes are usually tested for pancreatic cancer (29).
Currently, two imaging regimes are used to detect pancreatic cancer MRI
(magnetic resonance imaging) and EUS (endoscopic ultrasonography). Standard
radiological testings and CT scans are used for the detection of pancreatic
cancer; however, they are not sensitive enough to detect small early staged
tumors (30). Other methods like PET (positron emission tomography) are used to
detect metastases. Commercially available tumor marker for pancreatic cancer
CA19-9, is used to monitor the therapeutic response of patients. However,
limitations such as the percentage of patients with pancreatic cancer do not
7

secrete CA19-9 (10-15%) and the normal range of CA19-9 in patients with small
local tumors prevents CA19-9 from being used as a screening marker(31). Even
though CA19-9 is not used for diagnosis and detection of pancreatic cancer, it
strongly correlates with the progression of the disease and the response to
treatment. In many cases, even when the physician suspects pancreatic cancer
imaging tests fail to detect the tumor therefore biomarkers are needed to facilitate
diagnosis. For example, mutant K-ras is found in the pancreatic juice and in the
stool of patients with pancreatic cancer however, K-ras cannot be used as a
biomarker because of its presence among smokers and patients with chronic
pancreatitis. K-ras is also associated with late stages of the disease therefore it is
not an ideal biomarker (32).

Management and staging of pancreatic cancer
Pancreatic cancer staging is the most important factor in determining
treatment methods and management. The American Joint Committee on Cancer
(AJCC) use the TNM system to stage pancreatic cancer. T is the size of the
primary tumor and whether it has spread within the pancreas or locally- the tumor
is usually resectable, only 10-15% of patients belong to this category and are
candidates for surgery. The tumor is usually located at the head of the pancreas
and is detected early because of extreme pain. The Whipple procedure is
performed to remove the tumor. The procedure is highly invasive and requires
the removal of the duodenum, distal part of the stomach, gallbladder and the
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common bile duct, therefore this procedure is associated with mortality ranging
from 4-16%(33).The overall survival for patients with resectable pancreatic
cancer is 20% over 5 year. All patients who undergo surgical removal of the
tumor receive chemotherapy and radiation therapy. Recent studies show at least
10% long term survival benefit when chemotherapy and radiation follow surgery.
N describes the stage where the tumor has spread to regional lymph nodes- the
tumor is locally advanced. M is the stage where the tumor has metastasized to
other organs of the body. The numbers 0-4 indicate the severity of each stagethe tumor is metastatic(34). Tumors in the tail of the pancreas usually belong to
the N or M stage because of the late detection. This tumor is usually not subject
to surgery and chemotherapy slightly improves survival (35). Patients with locally
advanced tumors and patients who are not candidates for surgery undergo
palliative care to alleviate the pain. Jaundice is the most common symptom of
pancreatic cancer and is due to bile obstruction. To alleviate symptoms and clear
biliary obstruction associated with jaundice, endoscopic biliary stent insertion is
used. This method is the primary method for non surgical palliation of jaundice in
patients with pancreatic cancer. Incapacitating pain is another symptom of
pancreatic cancer. There are many causes of tumor associated pain that could
be caused by tumor infiltration, obstruction of the GI tract, tumor pressure and
more. Pain is usually treated by the administration of oral analgesics and at later
stages by morphine (36). In several cases, palliative surgery is used to alleviate
biliary obstruction, duodenal obstruction, and pain and to improve quality of life of
patients.

9

Chemotherapy
Up to 85% of patients are diagnosed with locally advanced pancreatic
cancer and metastatic cancer, therefore cannot be treated with surgery (37).
Adjuvant therapy with 5-fluouracil (5FU) combined with radiation had shown a
survival benefit in a study done in the 1980s (38). Recent studies have shown
greater long term survival in patients treated with 5FU after surgery compared to
patients who did not receive chemotherapy, however studies show that 5FU
combined with radiation showed no benefit (39). Nowadays, Gemcitabine is the
standard of care for patients with metastatic pancreatic cancer. Patients treated
with Gemcitabine have shown higher survival than patients treated with placebo
or 5FU (35). Therefore, Gemcitabine is considered first line therapy for advanced
pancreatic cancer (40). Several new agents have been tested alone or in
combination with Gemcitabine, however, the benefits were dismal. Gemcitabine
(29,29-difluoro 29-deoxycytidine, dFdC) is a cytidine analog. Like its analog AraC, Gemcitabine is a prodrug and is activated by cellular uptake and intracellular
phosphorylation by deoxycytidine kinase (dCK) into gemcitabine monophosphate
(dFdCMP) which is then converted into gemcitabine di (dFdCDP) and
triphosphate (dFdCTP), the active metabolites(41). Gemcitabine has many
antitumor effects (42); it inhibits DNA synthesis(43), DNA polymerase, induces
apoptosis and is incorporated in the DNA. Its location in the DNA chain prevents
its detection by DNA repair enzymes (44). Pancreatic cancer cells are highly
resistant to Gemcitabine. Resistance is either acquired after treatment or the
10

patient is resistant from the beginning. The response to Gemcitabine varies
between patients and this is mostly due to changes in the intracellular levels of
the metabolites and in the activities of drug transporters and enzymes involved in
the metabolism of the drug (45). An important determinant of a patients response
to Gemcitabine treatment is the intracellular retention of gemcitabine nucleotides
particularly gemcitabine tri phosphate.

Resistance to chemotherapy
As mentioned previously, most new trials have not shown significant
survival advantages and Gemcitabine is still the first line therapy for unresectable
pancreatic cancer. Preclinical investigations have identified many molecular
mechanisms that contribute to the resistance of pancreatic cancer to therapy. A
recent study shed the light on the tumor vasculature of pancreatic cancer (46).
Pancreatic cancer is hypovascular and poorly perfused. The poor network of
blood vessels impedes proper delivery of chemotherapeutic agents and increase
drug resistance (46). Another aspect of pancreatic cancer chemoresistance is the
alteration of genes involved in gemcitabine transport and metabolism. The
human equilibrative nucleoside transporter -1 (hENT-1) is the major gemcitabine
transporter in cells. In the absence or malfunction of hENT-1 gemcitabine cannot
exert its antiproliferative effects (47, 48). Low expression of hENT-1 In patients
correlates with low survival and bad prognosis (49). One of the most studied
mechanisms of pancreatic cancer resistance are related to ABC (ATP binding
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cassette) highly expressed in cancer cells and cancer stem cells (50). As
discussed previously, deficiency in dCK which phosphorylates gemcitabine into
its active form increases resistance. It has been reported that resistant pancreatic
cancer cell lines have reduced activity of dCK (51). Anti-apoptotic molecules are
overexpressed in pancreatic cancer which causes the cancer cell to evade
apoptosis thus reduces their chemosensitivity. For example, bcl-XL expression
levels are high in 82% of patients (52). Upregulation of bcl-2 has also been
correlated with increased resistance to gemcitabine (53) On the other hand, proapoptotic molecules are downregulated, for example BNIP3 expression is low in
almost 90% of patients (54) . The transcription factor nuclear-factor kappa B (NFkappaB) is constitutively expressed in pancreatic cancer and promotes tumor
grown, invasion, angiogenesis and chemoresistance (55, 56). The inhibition of
NF-KappaB increases chemo sensitivity and improves the outcome of pancreatic
cancer (55, 57).
Accumulating evidence shows that the dense tumor associated
desmoplasia plays a central role in chemo resistance. A recent study that uses
gemcitabine in combination with IPI-926 a hedgehog inhibitor that depletes the
stroma show increased survival and drug delivery compared to gemcitabine
treatment alone (46) therefore, desmoplasia hinders proper drug delivery and
might cause pancreatic cancer resistance to chemotherapy.

Pancreatic desmoplasia
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The hallmark of both chronic pancreatitis and pancreatic cancer is the
extensive fibrosis that develops in the pancreas. Pathological fibrosis is the
formation or development of excess fibrous connective tissue as a reparative or
reactive process. The fibrotic reaction that surrounds the pancreatic tumor tissue
is called desmoplastic reaction (Figure 1). This dense desmoplasia characterizes
the majority of pancreatic cancers (58), with the cancer cells constituting only a
minor population of the whole tumor mass. The stroma of pancreatic cancer is
composed of interstitial connective tissue mostly made of collagen I and
fibronectin, growth factors, inflammatory cells, new blood vessels, endothelial
cells, nerve cells, immune cells such as macrophages, dendritic cells and stellate
cells. The pancreatic stellate cell (PSC), which will be discussed in the next
section in more detail, is the major cell responsible for the production of the
desmoplastic reaction (59). Pancreatic tumor-stroma interactions are
bidirectional. Formation of new blood vessels in the stroma has been shown to
facilitate pancreatic tumor cell invasion (60). The stroma has also been
correlated with the degree of aggressiveness of pancreatic tumors; tumors that
have a less prominent stromal reaction are less likely to be aggressive (61). On
the other hand, the tumor also influences the stroma. One example is the
secretion of TGF-b by tumor cells which increases the production of Collagen I
and Connective Tissue Growth Factor (CTGF) by the stroma (62). Understanding
the molecular and cellular mechanisms of the stroma and how the tumor-stroma
interactions are influenced will be critical for identifying potential therapeutic
targets for pancreatic cancer.
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Figure 1. Desmoplastic reaction surrounding the tumor mass in
PDAC
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Pancreatic Stellate Cells (PSC)
Initiation
Pancreatic stellate cells are the principle source of fibrosis in both chronic
pancreatitis and pancreatic cancer (59, 63). Stellate cells are resident cells of the
pancreas, located at the basolateral aspect of acinar cells and constitute
approximately 4% of pancreatic cells (64). In the normal pancreas, stellate cells
are quiescent, identifiable by the presence of vitamin-A containing lipid droplets
in the cytoplasm (65) and positive immunostaining for cytoskeletal proteins such
as desmin and glial acidic fibrillary protein, which are the adopted way to identify
quiescent PSC. One of the normal physiological roles of PSC is in extracellular
matrix turnover via their ability to synthesize matrix proteins as well as matrixdegrading enzymes, MMPs. It has been suggested that PSC are involved in
maintaining pancreatic acinar cells because of their location around the acini.
Because of their periductal and perivascular location, PSC might be involved in
normal duct and vascular regulation in the pancreas (66).
Activation
During inflammatory injury, PSC undergo various changes in their morphology
and behavior, they become activated and assume a myofibroblast-like phenotype
characterized by the loss of vitamin A droplets, the production of -SMA and
extracellular matrix proteins such as collagen Ia1 and III, fibronectin and laminin
(64). In vitro studies have identified several factors involved in the activation of
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PSC such as alcohol (ethanol), cytokines (IL-1, IL-6), growth factors (platelet
derived growth factor; PDGF, TGF-b1, activin A), oxidative stress and pressure,
and changes in extra cellular matrix (67, 68). Other cells in the pancreatic
microenvironment such as macrophages, platelets and endothelial cells as well
as acinar cells and cancer cells are the source of PSC activating factors (67, 68).
Activated PSC proliferate, migrate, increase the production of extra cellular
matrix molecules as well as ECM related molecules and secrete cytokines and
chemokines (66, 69). Chemokines produced by PSC recruit inflammatory cells to
the pancreas. Cytokines and growth factors produced by PSC themselves and
other neighboring cells (acini, tumor, immune cells, platelets or any other cell in
the microenvironment) activate PSC and the reaction is bidirectional. Activation
occurs in both paracrine and autocrine manner (70). It has been suggested that
autocrine activation of PSC by cytokines like TGF-b, sustain the fibrotic response
and allows it to perpetuate after stimulation by the initial signal, which promotes
desmoplasia (33, 63). PDGF and TGF-b are believed to be the most potent
activators of PSC. PDGF induces the proliferation and migration of PSC (71, 72),
whereas TGF-b induces the expression of the activation marker alphaSMA and
ECM proteins to sustain the activation of PSC (73, 74). As mentioned previously,
PSC are involved in maintaining normal tissue architecture and ECM turnover,
and were shown to secrete MMPs (matrix metalloproteinases) such as MMP2,
MMP9 and MMP13, and TIMPs 1 and 2 (tissue inhibitors of matrix
metalloproteinases) (69) which could impact the invasion and metastatic potential
of pancreatic cancer. MMP2 is known to degrade collagen IV, an essential
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component of the basement membrane, thereby facilitating the deposition of
fibrillar collagen type I observed in pancreatic fibrosis. PSC promote the
angiogenic potential of cancer cells, so far two mechanisms have been identified.
The first mechanism involved the secretion of proteolytic matrix degrading MMP2 enzyme. Increased MMP2 expression by PSC has been shown to accelerate
pancreatic tumor progression (75) .The second known mechanism by which PSC
increase angiogenesis is by the production of proangiogenic factors such as
VEGF. When active, PSC constitutively produce vascular endothelial growth
factor (VEGF) and other angiogenic molecules such as VEGF receptors (flk-1, flt1) and others (76). Therefore, PSC play a profibrogenic and proangiogenic role,
and tumor induced PSC activation lead to increased angiogenesis, which could
promote pancreatic cancer progression by delivering oxygen and nutrients to the
hypovascular tumor in order to increase growth, invasion and metastasis.
Postactivation
Following activation, PSC have one of two fates depending on the severity of the
injury. If the injury is limited, activated PSC lose their active phenotype and
become quiescent again. PSC might also undergo apoptosis. In the latter two
cases, fibrosis does not occur. If the inflammatory is severe and repeated, PSC
activation is sustained and perpetuated and pancreatic fibrosis develops.
Repeated and sustained injuries to the pancreas are important for the
development of fibrosis. From this point on, pancreatic fibrosis is defined as the
pathological changes of extra cellular matrix composition, both in quality
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(collagen IV is replaced by collagen I and quantity (excessive collagen I
deposition) , caused by the irreversible activation of PSC.
Origin of PSC
There are many speculations about the embryonic origin of PSC. PSC share
similarities with their hepatic counterpart, hepatic stellate cells (HSC). Both cells
express alphaSMA, GFAP, and transcriptome analysis studies revealed 99.9%
homology at the mRNA level (77). This might suggest that PSC and HSC share a
common origin but have organ specific variations that could be due to the
different microenviromental factors the cell is exposed to. A different study
demonstrated that PSC are derived from a pancreas-specific precursor (78).
Activated PSC are thought to arise from quiescent PSC in the pancreas.
However, studies done on mice with sex-mismatched bone marrow (BM)
transplantation from a male mouse carrying enhanced GFP to female mouse
suggest that a small subgroup of PSC, approximately 5%, is derived from the BM
(79).

Molecular regulation of PSC
PPAR-

is a member of the PPAR family of nuclear hormone receptors.

Upon dimerization with RXR, PPAR-

binds PPAR response elements in the 5’

flanking region of target genes, therefore controlling cell proliferation,
macrophage function and immunity (80). Negative regulation of PPARassociated with PSC activation and overexpression of PPAR18

is

results in the loss

of PSC activation (81). Therefore, PPAR-

is involved in maintaining the

quiescence of PSC.
Rho and Rho kinase are also involved in the regulation of PSC.
Incubation of quiescent PSC with Rho kinase inhibitors (HA-1077 and Y-27632)
blocks the activation of freshly isolated PSC in culture on plastic (74). Rho
kinase inhibitors also inhibit stress fiber formation associated with activated PSC
migration and contraction in response to endothelin-1(82).
In activated PSC, a variety of stimuli activate the MAPK pathway including
ERK and p38MAPK (83). Activation of MAPK increases the production of
cytokines and chemokines by PSC. Studies show that inhibition of p38MAPK
blocks the activation of PSC (84) therefore, p38 MAPK mediates PSC activation.
ERK activation precedes alphaSMA expression and mediates PSC proliferation
to different stimuli in response to PDGF (83).
Phosphatidyl inositol 3 kinase (Pi3K)/ Akt pathway is also involved in the
regulation of PSC. Activation of PSC correlates with activation of PI3k/Akt
pathway (74). PDGF stimulates PSC migration via a PI3K/Akt dependent
pathway mediates however it was not found to be involved in PSC proliferation
(47, 85).
TGF-b is a potent regulation of PSC; it can regulate PSC in SMAD
dependent and SMAD independent mechanisms. The extra cellular matrix
production by PSC is regulated by TGF-b in a Smad2 dependent manner (86)
while TGF-b inhibits PSC proliferation by activating Smad3 dependent
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downstream signaling. Treatment of PSC with MEK1 inhibitors results in a
decrease in the mRNA levels of TGF-b1 thus demonstrating the involvement of
ERK pathway in the regulation of TGF-b.
Prostaglandin E2 (PGE2)
Prostaglandins (PG) are 20-carbon fatty acid derivatives found in all tissues and
organs. Diverse stimuli trigger PGs synthesis by the release of arachidonic acid
(AA) from the plasma membrane by the action of phospholipase-A2 (PLA2).
Upon its release from the plasma membrane, AA is converted to an unstable
endoperoxide intermediate prostaglandin G2 (PGG2) by cyclooxygenases; this is
rate limiting enzymatic reaction. PGG2 is then converted to an oxygenated
intermediate prostaglandin H2 by the peroxidase activity of COX- enzymes.
PGH2 is then metabolized by the action of cell specific synthases and is the
precursor of several prostaglandins; PGE2, PGD2, PGF2a, PGI2 and TXA2 (87).
Prostaglandins are released outside the cell immediately following their
biosynthesis. PG actions are dependent upon their interactions with prostanoid
specific G-coupled protein receptors, the focus will be on PGE2 and its four
receptors EP1-4. The actions of prostaglansins could also be terminated when
they are transported across the plasma membrane into the cytoplasm by
prostaglandin transporters (88) where they are reduced or oxygenated by PG
catabolizing enzymes (88, 89).
Currently, there are three known COX isoforms COX-1, COX-2 and COX3 (a splice variant of COX-1). COX-1 is a ubiquitously and constitutively
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expressed isoform that is postulated to have “housekeeping” functions with basal
production of prostaglandins under homeostatic conditions. In contrast, COX-2 is
encoded by an early-response gene and can be rapidly induced by growth
factors, cytokines, inflammatory mediators and tumor promoters (20, 90). By
immunohistochemistry (IHC), COX-2 was found to be highly expressed in chronic
pancreatitis (91) and pancreatic adenocarcinoma (92-94) and is also found in
precursor lesions associated with pancreatic cancer referred to as pancreatic
intraepithelial neoplasia (PanIN) (95) .
As mentioned previously, COX-2 is frequently overexpressed in many
types of cancer including breast, colon, lung and pancreatic cancer (96-98).
PGE2 has been identified as the major prostaglandin behind COX-2
proneoplastic functions [100]. Many tumors that overexpress COX-2 have high
intramural levels of PGE2. In pancreatic cancer, COX-2 overexpression was
reported in 74-100% of patients, irrespective of the grade and histological type of
the tumor (92, 95, 99). Furthermore, PGE2 promotes cell growth, angiogenesis,
migration, invasion and survival in pancreatic cancer (100-102). Many studies
have implicated the role of PGE2 in carcinogenesis for a wide range of cancers
including pancreatic cancer. However, the downstream targets by which PGE2
mediate these processes are not fully understood.
EP receptors subtypes
PGE2 exerts its effects by binding to four membrane bound E-prostanoid
(EP) receptors. In humans, there are four EP receptors EP1, EP2, EP3 and EP4.
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EP receptors are G-protein coupled receptors (GPRCs) that are activated by the
actions of PGE2. PGE2 binding to EP receptors produces a change in receptor
conformation, exposing intracellular sites involved in the interaction with the G
protein, consisting of α, β, and γ subunits. The interaction with the receptor
causes the guanosine diphosphate (GDP) to be freed from the α subunit and
replaced by guanosine triphosphate (GTP). The binding of GTP activates Gα
which dissociates from the Gβγ dimer and triggers a Gα-specific pathway. The
Gβγ complex can also activate a downstream pathway. Even though EP
receptors share common signaling mechanisms however, each receptor has
different biological effects (103, 104). All EP receptors are expressed on the
membrane (105) with EP3 and EP4 also exhibiting nuclear membrane
localization (106).
EP1 receptor is a 42-kDA protein that is particularly abundant in the
kidney and on smooth muscle associated with vessels. It has the least affinity for
PGE2. PGE2 binding to EP1 converts GDP Gαq to GTP Gαq which then
activates PLCβ. Upon its activation, PLCβ hydrolyzes phosphatidylinositol-4,5bisphosphate (PIP2) and generates diacylglycerol (DAG) and inositol-1,4,5trisphosphate (IP3) which is associated with the release of CA++ from
intracellular stores. The activation of EP1 downstream signaling alters the activity
of many proteins including activation of PKC (107) . Studies implicate EP1
receptor in colon carcinogenesis (108).
EP3 receptor is unique among other EP receptors because of its 7
alternative splicing variants defined by their C-terminal cytoplasmic tails. EP3
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activation usually inhibits cAMP production by inhbiting adenylate cyclase via the
activation of Gi (104). However, EP3 receptor has been shown to couple go Gi,
Gs and Gq protein therefore, the role of EP3 receptor may vary depending on the
cell type.
EP2 receptor is a 53 kDa protein that upon coupling to Gs increases
cAMP levels and activation of protein kinase A (PKA) signaling. Activation of
cAMP/PKA pathway is associated with growth and proliferation. Phosphorylation
of PKA activates Akt which inhibits GSK-3. Inhibition of GSK-3 relieves the
phosphorylation of β-catenin, therefore allowing it to translocate to the nucleus,
which results in an increase in cell proliferation (109). EP2 receptor can also
activate proliferation by association with Axin which inactivates and releases
GSK-3b causing β-catenin activation and translocation to the nucleus. EP2
receptor is heavily involved in tumor development and progression in many
organs and tissues such as breast, prostate, skin and pancreas (110, 111) (112,
113).
EP4 receptor also increases cAMP levels in a similar manner to EP2
receptor. In addition to cAMP/PKA pathway, EP4 receptor activates PI3K/AKT
signaling. Activation of EP4 receptor leads to the phorphorylation of extra cellular
signal regulated kinases (ERKs) by PI3K (114) which activates early growth
factor-1 (EGR-1). EGR-1 is known to regulate many genes important in cancer
and inflammation such as PGE2 synthase, TNF-α and cyclin D1. Knock out
studies of EP4 receptor has shown a role for EP4 in cancer and inflammation
(115-117).
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Targeting COX-2/PGE2
COX-2 and PGE2 inhibition have been considered a potential
chemotherapeutic target for pancreatic cancer. Several drugs that target COX-2
have been developed in the past decade, the most notorious of which is the
COX-2 inhibitor is Celecoxib. Celecoxib is a non-steroidal anti-inflammatory drug
(NSAID) and is a highly selective COX-2 inhibitor. Traditional NSAIDs inhibit both
COX-1 and COX-2, while celecoxib is more selective for COX-2 inhibition. COX-1
inhibits prostaglandin and thromboxanes, while COX-2 inhibits prostaglandin
production alone. COX-2 inhibition thus spares thromboxane without any effect
on platelet aggregation or blood clotting. Selective inhibition of COX-2 by
celecoxib was effective in suppressing the growth of pancreatic cancer cells in
vitro (118) and in inhibiting tumor growth and angiogenesis in orthotopic
implantation tumor models (119). But the treatment of pancreatic cancer patients
with celecoxib alone or in combination with standard chemotherapeutic drugs
was not effective in reducing the pancreatic tumor in advanced staged but also
was highly toxic to patients (120). Patients treated with COX-2 inhibitors
particularly, celecoxib had a high risk for heart attack and strokes. In a clinical
trial for colon cancer prevention, patients treated with celebrex, a COX-2
inhibitor, showed a high risk for cardiovascular diseases compared to the
placebo (121).The toxicity behind COX-2 inhibition is mainly due to the unspecific
inhibition of all prostaglandins. Inhibition of COX-2 causes a shift in the
PGI2/TxA2 balance. Prostacyclin I2 (PGI2) has anti proliferative, anti aggregating
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and vasodilating functions, whereas Thromboxane (TxA2) is a vasoconstrictor
that has smooth muscle proliferating effects and causes platelet aggregation.
The PGI2/TxA2 balance is essential to maintain vascular homeostasis and the
disruption of the balance, which could be caused by COX-2 inhibition, causes
thrombosis (122). COX-2 inhibitors have also been reported to increase blood
pressure because of the high levels of TxA2. Therefore, emphasis has been on
finding an alternative route to block PGE2 production, downstream of COX-2, to
avoid the toxic side effects seen when COX-2 is inhibited. Inhibition of PGE2
could be achieved by either increasing its inactivation by 15-PGDH or by
targeting the inhibition of EP receptors. 15-PGDH is an enzyme that catalyzes
the oxidation of the 15(S)-hydroxyl group of prostaglandins leading to the
formation of metabolites with decreased activities compared to PGE2 (123),
therefore, biologically inactivating PGE2. 15-PGDH has been shown to be a
tumor suppressor gene that is down regulated in breast, lung, colon and bladder
cancers (124-127). A study done in colon cancer shows that reintroducing 15PGDH to CD11b myeloid cells inhibits PGE2 inflammatory, immunosuppressive
functions and increased survival. 15-PGDH inhibition of PGE2 was also
associated with inhibition of inflammatory cytokines such as IL-6, IL-10, IL-β and
of immunosuppressive cytokine IL-13 (128).
An alternative way to block PGE2 production is by the inhibition of one of
more EP receptor. As discussed previously, PGE2 exerts its actions through
binding to one of its four receptors EP1-4. A number of studies support the role of
each EP receptor in tumorigenesis and inflammation. Recently, EP receptors
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have been targeted for the treatment and/or prevention of cancer. Synthetic
drugs, that act as antagonists or agonists for EP receptors, have been developed
by pharmaceutical companies, and tested in vitro for their anti tumor effects
(129). Treatment of breast cancer with an EP4 antagonist shows a reduction in
metastasis compared to the untreated control (130). In another study done in
colon cancer, inhibition of EP1 and EP4 receptor showed a decreased number
and size of polyps (131).
PGE2 and fibrosis
COX-2 expression is considered a major factor linking chronic
inflammation with metaplastic and neoplastic changes in pancreas (96). The
expression of COX-2 in chronic pancreatitis was localized in the cytoplasm of
pancreatic acinar cells, islet cells, and ductal cells but not in the surrounding
stromal cells or infiltrating Inflammatory cells, while in pancreatic
adenocarcinoma it was localized only to cancer cells and not to the stromal or
inflammatory cells (92). In the pancreas the fibrotic process is associated with
Inflammation and high levels of COX-2 activity (91, 132). COX-2 activity leads to
increased production of the prostaglandin PGE2 at sites of inflammation in
human tissues (91). PGE2 has both pro-inflammatory and cell-protective
activities, but its specific roles in pancreatic disease are unknown. PGE2 mediate
a wide away of physiological and pathological functions in different organs and
tissues, such as inflammation.

26

PGE2 and the tumor microenvironment
It is now well known that the stroma surrounding the tumor cells aids in the
development and progression of cancer. A number of tumor associated stromal
cells express high levels of COX-2, however, not much is known on the role of
PGE2 and its receptors in the stroma. In colon cancer, over expression of COX-2
in the stromal cells increased the proliferation of colon cancer cells and VEGF
production. Blocking EP4 receptor on the stromal cells blocked those effects
completely. These results suggest that regardless of the status of COX-2 in
cancer cells, blocking COX-2 or EP receptors could block tumor –stroma
interactions (133). Another study done in colon cancer identifies a role for stromal
EP4 receptor in metastasis (134). EP4 knock out in the stroma showed a
reduction in tumor growth and metastasis. In a study done on sarcoma cells, EP3
receptor knock out in the stromal cells reduced angiogenesis and tumor growth,
further supporting the role of PGE2 produced by the stroma in tumor
development and angiogenesis (135). Studies where EP receptors are inhibited
and studies that target the increase of 15-PGDH (128) activity demonstrate a
vital role for PGE2 in the stroma of tumors.

Stromal PGE2 in pancreatic cancer
The role of PGE2 in the stroma of pancreatic cancer is not fully
understood, as only a limited number of studies have aimed to determine the role
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of PGE2 in the stroma of pancreatic cancer. As discussed previously, pancreatic
and hepatic stellate cells share many similarities and studies from hepatic stellate
cells are used to understand the behavior of pancreatic stellate cells. In a study
done on HSC in vitro, treatment with NS-398, a COX-2 inhibitor, reduced the
expression of alpha smooth muscle actin, which is an activation marker for
stellate cells. Therefore indicating that COX-2 might play a role in the activation
of HSC (136). In another study, celecoxib induced HSC apoptosis through the
inhibition of Akt activation which resulted in a reduction of fibrosis (137). One of
the few studies that examine the role of COX-2 in pancreatic stellate cells shows
that COX-2 is expressed and required for PSC to respond to inflammatory
cytokines (138). However, this study focuses more on the role of TGF-β in
activating COX-2 expression in PSC and does not investigate the role of stromal
COX-2/PGE2. The role of COX-2/PGE2 in the stroma of PDAC is not
understood. There are no studies examine the role of PGE2 or its receptors in
the regulation of stromal activation in pancreatic cancer. As mentioned
previously, COX-2 expression is high in both chronic pancreatitis and pancreatic
cancer which suggest that COX-2/PGE2 play a role in the regulation of
pancreatic stellate cells, however the precise mechanism is unknown.
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EXPERIMENTAL RATIONALE AND HYPOTHESIS
As discussed above, pancreatic ductal adenocarcinoma, also called the
“silent killer”, is a highly lethal disease that is often asymptomatic, with a reported
5-year survival rate of less than 5%. In western countries, PDAC is the fourth
most common cause of cancer related death. Currently, the therapies available
for pancreatic cancer show only a modest increase in survival rate; patients have
a 6 month median survival rate. A distinct feature that characterizes PDAC is the
extensive desmoplastic reaction that surrounds the tumor. PSCs produce the
majority of the fibrosis associated with PDAC and most lines of evidence indicate
that PSC promote tumor development and progression. Therefore, it is clear that
more research to understand the stroma of pancreatic cancer is needed in order
to develop novel therapies with the hope of improving patients’ prognosis.
Based on the available evidence, the hypothesis for this dissertation was
that PGE2 regulates PDAC stromal activation by increasing the activity of PSC in
an invitro model using immortalized pancreatic stellate cells from a patient with
pancreatic cancer. This dissertation addresses the regulation of PSC by PGE2
and determines the receptor critical for mediating PGE2 dependent functions in
fibrosis. In order to accomplish this, in the first aim, stromal activation in
pancreatic cancer was “dissected” in vitro, and the effects of PGE2 on each step
were determined by measuring changes in PSC functions. This aim assessed the
levels of COX-2/PGE2 produced by PSC and examined the effects of
exogenous PGE2 on proliferation, migration, invasion potential of PSC as well as
changes in extra cellular matrix after treatment with PGE2.
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The second aim of this dissertation explores the mechanism by which
PGE2 regulates PSC, focusing primarily on determining which EP receptors are
involved in mediating PSC activity by PGE2 and what signaling pathways
activated downstream of PGE2 in PSC. In addition, this aim addresses
modulation of PSC “fibrotic” functions by blocking EP4 receptor activity in vitro to
determine the role of EP4 as a potential therapeutic target.
The third aim of this dissertation examines the mechanisms of PGE2 on
stromal activation in pancreatic cancer at the molecular level by determining the
EP4 dependent downstream signaling pathways activated and by determining
the role of PGE2 in regulation Collagen I, focusing on the expression and
transcriptional activity of Collagen I gene. This aim also determines the role of
blocking EP4 receptor on Collagen I gene. The last part of this chapter aimed at
identifying the area in the promoter of collagen I regulated by PGE2.
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CHAPTER TWO: PROSTAGLANDIN E2 REGULATES THE ACTIVATED
PHENOTYPE OF PANCREATIC STELLATE CELLS

31

INTRODUCTION

Pancreatic fibrosis is the formation or development of excess fibrous
connective tissue in pancreas as a reparative or reactive process (139). The
hallmark of chronic pancreatitis and pancreatic cancer is pancreatic fibrosis. It is
the inflammation of the pancreas. Inflammation is associated with a high increase
of COX-2 activity (140) .COX-2 activity leads to increased production of the
prostaglandins PGE2 at sites of inflammation in human tissues. PGE2 has both
pro-inflammatory and cell-protective activities. COX-2 and PGE2 are correlated
with worse prognosis in many cancers like lung, gastric and pancreas (141).
Prostaglandin

endoperoxide

synthase,

commonly

referred

to

as

cyclooxygenase (COX), catalyzes the double oxygenation and reduction of
arachidonic acid (AA), after its release from membrane glycerophospholipids by
phospholipase A2 (PLA2), to the intermediate form prostaglandin H2 (142) which
is further metabolized to form prostaglandin E2 catalyzed by microsomal PGE2
synthases (143). Currently, there are three known COX isoforms COX-1, COX-2
and COX-3 (a splice variant of COX-1). COX-1 is a ubiquitously and
constitutively expressed isoform that is postulated to have “housekeeping”
functions with basal production of prostaglandins under homeostatic conditions.
In contrast, COX-2 is encoded by an early-response gene and can be rapidly
induced by growth factors, cytokines, inflammatory mediators and tumor
promoters (144). By immunohistochemistry (IHC), COX-2 was found to be highly
expressed in chronic pancreatitis (91), pancreatic adenocarcinoma (92-95) and
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pancreatic intraepithelial neoplasia (PanIN) (145). The expression of COX-2 in
chronic pancreatitis was localized in the cytoplasm of pancreatic acinar cells, islet
cells, and ductal cells but not in the surrounding stromal cells or infiltrating
inflammatory cells (91), while in pancreatic adenocarcinoma also it was localized
only to cancer cells and not to the stromal or inflammatory cells (92) .COX-2
overexpression is an established factor linking chronic inflammation with
metaplastic and neoplastic changes in pancreas (96). Transgenic overexpression of COX-2 in the pancreas has been shown to lead to the
development of pancreatic fibrosis (96). Despite the correlation between COX-2
and fibrosis, the mechanisms involved in COX-2 mediated stromal activation in
pancreatic cancer are unclear.
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and is a
highly selective COX-2 inhibitor. Traditional NSAIDs inhibit both COX-1 and
COX-2, while celecoxib is more selective for COX-2 inhibition. COX-1 inhibits
prostaglandin and thromboxanes, while COX-2 inhibits prostaglandin production
alone. COX-2 inhibition thus spares thromboxane without any effect on platelet
aggregation or blood clotting. Selective inhibition of COX-2 by celecoxib was
effective in suppressing the growth of pancreatic cancer cells in vitro (146) and in
inhibiting tumor growth and angiogenesis in orthotopic implantation tumor models
(119). But the treatment of pancreatic cancer patients with celecoxib alone or in
combination with standard chemotherapeutic drugs was highly toxic to patients
(120).
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Stellate cells are resident cells of the pancreas, located at the basolateral
aspect of acinar cells (147). In the normal pancreas, stellate cells are quiescent,
identifiable by the presence of vitamin-A containing lipid droplets in the cytoplasm
and positive immunostaining for cytoskeletal proteins such as desmin and glial
acidic fibrillary protein. In health, PSC play a role in extracellular matrix turnover
via their ability to synthesize matrix proteins as well as matrix-degrading
enzymes, MMPs. During necroinflammatory injury, PSC become activated and
assume a myofibroblast-like phenotype characterized by the loss of vitamin A
droplets, the production of a-SMA and extracellular matrix proteins such as
collagen I and III, fibronectin and laminin (148). Factors known to be upregulated
during pancreatic injury such as TGF-b, platelet-derived growth factor (PDGF)
and proinflammatory cytokines, stimulate PSC proliferation and production of
extracellular matrix proteins (149). Notably, activated PSC also produce
increased amounts of matrix metalloproteinase-2 (MMP2) (69), known to
degrade collagen IV, an essential component of the basement membrane,
thereby facilitating the deposition of fibrillar collagen1a as observed in pancreatic
fibrosis. But, the exact mechanisms regulating stellate cells and their
development of pancreatic desmoplasia are not fully understood.
In the current study, I sought to further understand the role of PGE2 on
stromal activation in pancreatic cancer in vitro using human pancreatic stellate
cells from a patient with PDAC. I determined that PGE2 might be a useful target
for novel therapies and that targeting prostaglandin pathways may be a strategy
to interfere with stromal activation in pancreatic cancer. Hence, I have
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investigated the effects of PGE2 on pancreatic stellate cells. As a measure to
study stromal activation in pancreatic cancer, primary human pancreatic stellate
cells (PSC) from a patient with pancreatic cancer, were isolated and immortalized
as mentioned in previous publications (68). These studies showed that, PSCs
cells express COX-2 and secrete PGE2 and PGE2 has autocrine effects on
stellate cells. Exogenous addition of PGE2 on PSC stimulated the migration and
invasion of stellate cells and also production of extra cellular matrix (ECM)
proteins – fibronectin, collagen 1a, HSPG2, vimentin and elastin; and production
of matrix metalloproteinases (MMP) – 2 & 9. Thus, this study provides a better
understanding on regulation of stellate cells by PGE2 and further the role of
stellate cells on pancreatic stromal activation in pancreatic cancer. This study
suggests that PGE2 could be an alternative potential therapeutic target to reduce
COX-2 mediated stromal hyperactivation associated with chronic pancreatitis and
pancreatic cancer.
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MATERIALS AND METHODS

Materials
Culture media and fetal bovine serum (FBS) were obtained from Life
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman
Chemicals.

Cell Culture
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth
method from pancreatic adenocarcinoma samples from patients undergoing
surgical resection and were immortalized (68)(Hwang RF, 2008). PSCs were
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in
10% DMEM containing 1% antibiotic. PGE2 was purchased from Cayman
Chemicals (Ann Arbor, MI).
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Invasion and Migration assays

For studies of cell invasiveness, BIOCOAT Matrigel invasion chambers (BD
Biosciences, Chicago, IL) were used. Briefly , 2 x 105 cells in 100 ul of serum-free
medium were added to the upper chamber and different concentrations of PGE2
(1–1000 nM) in 0.5% serum containing DMEM were added into the lower
chamber. The cells were allowed to invade the Matrigel for 22 h at 370C in a 5%
CO2 atmosphere. DMEM containing 0.5% serum was used as control. The noninvading cells on the upper surface of the membrane were removed with a cotton
swab and the invading
\cells on the lower surface of the membrane were fixed and stained with a DiffQuick stain kit (BD Biosciences), washed twice with water and air-dried. Invading
cells in three adjacent microscope fields for each membrane were imaged at 20x
magnification. To assess cellular migratory potential, the protocol described
above was used, except that migration chamber devoid of matrigel was used (BD
Biosciences, Chicago, IL). Experiments were performed at least in triplicate, and
the results were shown as mean ± SD of three independent experiments

MTS proliferation assay

MTS was obtained from Promega. MTS is a tetrazolium salt that undergoes a
color change caused by its bioreduction of MTS into a water-soluble formazan.
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The conversion of MTS into the aqueous-soluble formazan is accomplished by
dehydrogenase enzymes found in active mitochondria and is such that the
reaction occurs only in living cells. The quantity of formazan product measured
by the amount of 490-nm light absorbance is directly proportional to the number
of living cells in culture. MTS (2 mg/ml; pH 6.5) was dissolved in PBS and filter
sterilized. A 3-mM PMS solution was also prepared (in PBS) and filter sterilized.
These solutions were stored at −20°C in light-protected containers. MTS (100µ l)
was added to each well. After incubation at 37°C in a humidified atmosphere with
5% CO2 for 1 hours, the optical density was measured at 490 nm by means of
spectrophotometry. Cell growth was analyzed by means of MTS assay after 0,
24, and 48 hours of culture. Cell proliferation was analyzed with a
hemocytometer and a cell counter (Coulter, Hialeah, FL).

Apoptosis detection

To define the level of apoptosis, PSC cells were trypsinized, pelleted, fixed, and
propidium iodide (PI) stained. Propidium iodide fluorescence activated cell
sorting analysis (PI-FACS). Cells were seeded onto 6-well plates at 2x106
cells/plate. The next day, media was aspirated and replaced with low serum
0.5% FBS containing media. After 24 hours of starvation, PSC were treated with
PGE2 (50 or 100 nM) or DMSO for 24 hrs. Twenty four hrs after PGE2 treatment,
media and cells were collected and fixed in 75% cold ethanol. Cells were stained
with PI (50 µg/ml) and analyzed by flow cytometry (Beckman Coulter, Inc).
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Reverse transcription-PCR

Total RNA was isolated from PSC with and without siRNA transfection and the
quality of RNA was tested as mentioned previously. DNAse was used to remove
contaminating genomic DNA and RNA purification. Quality of the RNA was
confirmed by running on a denaturing gel, and we have observed clear 28S and
18S rRNA bands. A non reverse transcribed control was used to assure that no
genomic DNA was amplified. Primers were designed for human
MMP-2

(5’

CTTCTTGTCGCGGTCGTAGTCCTC3’)

(3’

TGGCGATGGATACCCCCTTGA5’) ,
MMP-9

(5’

GCGCTGGGCTTAGATCATTCCTCA

3’)

(3’

GCAGCGCGGGCCATTGTC 5’) ,
MMP-1

(5’

ATTCTACTGATATCGGGGCTTTGA3’)

(3’

TGTCCTTGGGGTATCCGTGTGTAG5’) ,
MMP-7

(5’

AAACTCCCCGCGTCATAGAAATAAT

3’)

(3’

3’)

(3’

3’)

(3’

TGAGTTGCAGCATACAGGAAGTT 5’),
MMP-11

(5’

CTGGCGGGCGCTGGGAGAAGAC

CAGGGCTGGCCATATAGGTGTTGA5’),
TIMP-1

(5’

CGTCATCAGGGGCCAAGTTCGTG

GAGGCAGGCAGGCAAGGTGAC 5’),
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TIMP-2

(5’CTGGCGGGCGCTGGGAGAAGAC3’)

(3’CAGGGCTGGCCATATAGGTGTTGA3’)
Fibronectin

(5’

CCGCCACGTGCCAGGATTACC

3’)

(5’

3’)

(3’

AGGGGCTCGCTCTTCTGATTATTC 3’) ,
Vimentin

(5’

GGTCCGTGTCCTCGTCCTCCTAC

CGCGGGCTTTGTCGTTGGTTA 5’) ,
Elastin

(5’

GGACCCCTGACTCACGACCTC

3’)

(5’

ACTTGGCCGCTCCCCTCTTGTTTC 3’),
HSPG2

(5’

CCGCCAGGGCAGGTCA

3’)

(3’

GGTGGGCAGCGGTAGGAAGGAGTA 5’),
COX-2

(5’GGTCTGGTGCCTGGTCTGATGATG3’)

(5’

GTCCTTTCAAGGAGAATGGTGC 3’).
The amplified products were separated on 1.5% agarose gels and visualized by
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which
was used as a loading control for the PCR reactions, were forward 5' ATG ATA
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG
AA 3'.

Immunohistochemical Staining for COX-2
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Unstained 4uM tissue sections from human patients were deparaffinized with
xylene and rehydrated with ethanol. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in methanol and non specific binding sites were
blocked with protein blocking solution (5% normal horse and 1% normal goat
serum). Primary antibody against COX-2 (1:800 dilution; cat # HPA001335 ) was
added and the samples were incubated overnight at 4°C. The secondary
antibody was added and incubated for 1 hour at room temperature. Finally, slides
were developed with 3,3 diaminobenzidine substrate (DAB) and counterstained
with hematoxylin. Then the slides were dehydrated with ethanol, fixed with xylene
and mounted. Immunohistochemistry was analyzed using an inverted light
microscope (Olympus, Center valley, PA). Images were captured using a chilled,
charge coupled device camera (Hamamatsu, Bridgewater, NJ) and smartcapture
software (Digital Scientific, Cambridge, UK).

Statistical analysis

All experiments were conducted in triplicates and carried out on three or more
separate occasions. Data presented are means of the three of more independent
experiments +/- standard error mean (SEM). Statistical analysis was done using
GraphPad Prism (GraphPad Software). Comparisons were made using two-tailed
Student's t test and significant difference was defined as P < 0.05. Data are
shown as mean ± SE.
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RESULTS

COX-2 is overexpressed in PDAC and PSC produce high levels of PGE2
The immunohistochemical analysis of COX-2 expression in tissue sections from
pancreas resected from human pancreatic tumors showed high levels of staining
intensity of COX-2 compared to normal pancreas tissues (Figure 2.1.1). PDAC
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showed high patterns of expression from low staining to high staining. In order to
determine whether COX-2 plays a role in the pancreatic stroma, I examined if
PSC express COX-2. mRNA was amplified from immortalized PSCs (line 1 and
2) and RT-PCR showed that all PSC examined express COX-2 (Figure 2.1.2).
Furthermore, to determine whether PGE2 is secreted by the PSCs, I quantified
the levels of PGE2 both intracellularly and media bathing the stellate cells. I
employed Liquid Chromatography- tandem mass spectrometry, which is able to
distinguish geometrical isomers and accurately measure levels of different
prostaglandins produced. PGE2 had an intracellular concentration of 20 ng/ml,
being the highest among all other ecosanoids examined. Even at the secreted
levels of ecosanoids, PGE2 levels were the highest among the prostaglandins
examined (260 ng/ml) (Figure 2.1.3). PGE2 was found in the media bathing the
cultured PSCs, indicating that this mediator is released by the PSCs into the
microenvironment. This data indicates that PGE2 is highly present and produced
by PSC. It is already known that PGE2 are secreted by pancreatic cancer cells.
Therefore, there are at least two potential sources that account for the production
of PGE2 in the stroma. This also suggests that PGE2 plays a role in the
regulation of the tumor microenvironment and not only the cancer cells.
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Figure 2.1 Ecosanoid levels in PDAC and PSC (1) Human tissue sections
were immunostained for COX-2 and their respective serial sections with H&E.
IgG was used as a control and showed no immunoreactivity (data not shown).
COX-2 expression was not detected in the sections containing normal pancreas.
In cancer sections, COX-2 is upregulated when compared to the normal
pancreas and positive staining in found in the ductal compartment of the
pancreas (x400 magnification).(2) RT-PCR showing the expression of COX-2 in
PSC.(3)Liquid Chromatography tandem mass spectrometry showing the levels of
ecosanoids intracellularly;cell pellet was collected and subjected to LC MS MS to
determine the concentration of ecosanoids. The media bathing PSC was
collected and subjected to LC MS MS to determine the levels of ecosanoids
extracellularly.
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PGE2 stimulates migration, invasion in PSC

To determine the effects of PGE2 on the functions of stellate cells, I
looked at phenotypic changes in PSCs caused by PGE2 treatment in vitro. First,
the migration potential of PSCs was assessed using a conventional Boyden
Chamber assay, with the control or PGE2 in different concentration was added to
the bottom chambers to determine if PGE2 acts as a chemoattractant that
induces PSC migration. I treated PSCs with PGE2 in vitro. PSC re-suspended in
0.5% serum containing media (2x104) was plated on migration chambers with
and without PGE2 (0-1000nM). After 22hrs, cells migrated to the bottom side of
the chamber were fixed with methanol and stained with hematoxylin and number
of cells migrated or invaded was counted on at least 10 fields looking under the
microscope. Exogenous addition of PGE2 induced a dose dependent significant
increase in PSC cell migration (Figure 2.2) in vitro with an optimal concentration
being 100nM of PGE2. Next, I looked at the effects of PGE2 on the invasion
potential of PSC and its ability to penetrate through Matrigel, using a modified
Boyden Chamber assay. PSCs were plated at a confluency of 2x104 cells per
well (upper chamber) after being incubated in near starvation conditions (0.5%
serum containing media) for 24 hours. The bottom chambers contained different
concentrations of PGE2 or the vehicle. 10% FBS was used as a positive control.
After 22hrs, cells invaded through the matrigel matrix to the bottom side of the
chamber were fixed with methanol and stained with hematoxylin and number of
cells invaded was counted on at least 10 fields looking under the microscope.
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The wells that did not have PGE2 showed no PSC invasion. However, PGE2
increase PSC invasion at concentrations ranging from as little as 25nM of PGE2
to 1000nM PGE2 after 22 hours (Figure 2.3). The maximum invasive effects
were detected at 100nM PGE2. Therefore, PGE2 stimulates both PSC migration
and invasion in a dose dependent manner compared to the untreated control.
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Figure 2.2 Effects of PGE2 on PSC migration PSC migration was evaluated
using a Boyden chamber assay. PSC (20 x 103 cells/well) were plated in the
upper Boyden Chamber in serum free media. The lower wells contained
0,10,25,50,100,500,1000nM) of PGE2. Cells were stained with H&E and the
number of cells migrated was calculated. PSC stimulated with PGE2 for 6 hours
(data not shown *, P<0.05
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Fig
ure
2.3
Eff
ect
s of
PG
E2
on
PS
C invasion PSC invasion was assessed by modified Boyden chamber assay.
PSC (20 x 103 cells/well) were plated in the upper chamber of the apparatus and
different concentrations of PGE2 were added to the lower chambers. Cells were
stained by H&E and cell invasion through matrigel was calculated. P<0.05 versus
control.
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PGE2 stimulates changes in PSCs gene expression

In order to see if stimulation of PSC with high levels of PGE2 affects
stromal gene expression, PSCs were incubating in 0.5% serum containing media
for 24 hours for serum starvation, next RNA was extracted from PSC treated with
PGE2 (100nM) and control treated with the vehicle (DMSO) and converted to
cDNA. Using RT-PCR with specific primers for each gene, I looked at changes in
the expression of the following genes: HSPG2, vimentin, fibronectin and elastin
(Figure 2.4.1) which are known to be involved in fibrosis and were found in
microarray studies from our laboratory to be high in the stroma, therefore called
“stromal genes”. This data shows that PGE2 addition to PSCs stimulated the
expression of the above mentioned genes therefore indicating the stimulatory
effects of PGE2 on stromal gene expression.
To further investigate the role of PGE2 in PSCs activation, changes to the
expression pattern of genes involved in matrix turnover were assessed. I looked
at changes in the expression of a panel of MMPs and TIMPs after PGE2
treatment compared to the untreated control (Figure 2.4.2). I found that PGE2
addition, increases PSC gene expression of MMP-2, MMP-3, MMP-9, and TIMP1 whereas the expression of MMP-11 and TIMP-2 remained unchanged.
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Figure 2.4 Effects of PGE2 on PSC gene expression: (1) RT-PCR showing
the expression of HSPG2,Elastin,Fibronectinm,Vimentin before and after
stimulation with PGE2. 100nM PGE2 was added to PSC after over night serum
starvation and left for 24 hours. B-actin was used as a control.(2) RT-PCR the
expression of MMP-2, 3, 9, 11 and TIMP-1,2 before and after stimulation with
PGE2. 100nM PGE2 was added to PSC after over night serum starvation and left
for 24 hours. B-actin was used as a control. *, P<0.05
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PGE2 stimulates the proliferation of PSC

To examine the role of PGE2 on PSC proliferation and growth, PSC were
incubated in near starvation conditions for 24 hours and treated with PGE2 in
doses ranging from 10nM to 1000nM. As a negative control, the vehicle for
PGE2, DMSO was added to PSC separately. PSC proliferation was analyzed by
means of a non radioactive MTS assay after 0, 24, 48 hours of PGE2 treatment.
PGE2 addition to PSC induced an increase in proliferation seen at 100nM PGE2
added for 24 hours (Figure 2.5). Results were confirmed by the cell counter and
hemocytometer proliferation assays (data not shown here).There was no
significant different between addition of PGE2 for 24 hours or 48 hours (data not
shown).
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Figure 2.5 Effects of PGE2 on PSC Proliferation PSC proliferation was
measured by MTS assay. PSC (1000 cells) were plated on a 96-well plate and
serum starved overnight. PGE2 (10,100,500 nM) were exogenously added to the
plates and estimated after 24 hours by MTS assay. PGE2 stimulates the
proliferation of PSC*, P<0.05
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PGE2 did not affect PSC apoptosis

To determine the effects of PGE2 on PSC apoptosis, I looked at PGE2
induced PSC apoptosis by propidium iodide (PI) staining. I analyzed by FACS
the level of apoptosis of PSC treated with 0, 50 and 100nM PGE2 over 24 and 48
hours (data for 48 hours is not shown). The percentage of PSC stained with PI
and analyzed by FACS did not change when PGE2 was added to the cells,
therefore PGE2 did not affects the apoptosis level of PSC (figure 2.6). No effects
of PGE2 treatment was observed on the fraction of the cells underdoing DNA
synthesis stage of the cell cycle (data not shown).
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Figure 2.5. Effects of PGE2 on PSC survival and apoptosis PSC apoptosis
and survival was assessed by FACS analysis and PI staining. PSC were treated
with 0 and 100 nM PGE2 for 24 hours and subjected to propidium iodide staining.
Representive experiment is shown. Statistics were perfomed as described in
methods. No statistical difference between PGE2 treated cells and the negative
untreated control. *, P<0.05
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DISCUSSION

PSCs have recently become the focus of much attention due to their
importance in PDAC. However, these cells also play a critical role in CP. In both
diseases PSCs become activated and produce an abundant desmoplastic
response. Many factors are known to regulate PSC activity including regulatory
molecules such as TGFb, PDGF, CTGF and others. Studies have shown that
addition of TGFb results in an increase in PSC activation and subsequent
increase in contractility, matrix degradation, proliferation and MMP and TIMP
production(150, 151) Furthermore, studies have shown that COX-2 is high in
both CP and PDAC therefore suggesting a potential role in stromal
hyperactivation related associated with PDAC. Many studies have shown that
COX-2 levels positively correlates with the aggressiveness of PDAC (141) (96)
and that blocking COX-2 (152) significantly reduces the tumor size and
metastatic potential. There have been suggestions that the activity of COX-2 and
prostaglandins influence PSC (153). However, the role of COX-2 and PGE2 has
not been fully assessed in the stroma of PDAC. This study aimed at identifying
the functional role of COX-2 and its downstream effector PGE2 in the stroma,
particularly by examining PGE2 dependent alterations in the profibrogenic
phenotype of PSC. I have dissected the stromal hyperactivation related
associated with PDAC into five major responses that contribute to the
development of the fibrogenic phenotype that follows quiescent PSC activation in
response to inflammation; proliferation, migration, penetration (invasion),
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alteration of matrix composition (over expression of stromal genes) and
apoptosis. A major aspect of fibrosis is the changes in extra cellular matrix
composition. During fibrosis, the matrix composition shifts from a normal matrix
rich in collagen IV rich basal lamina to a fibril forming collagen I. These findings
show that upon stimulation with PGE2 serum starved PSC highly increase their
expression of several genes involved in matrix formation such as HSPG2,
fibronectin and elastin. Matrix MetalloProteases (MMPs) are also involved in
fibrosis, particularly MMP-2 and MMP-9. MMP-2’s primary function is the
degradation of Collagen IV. The following step in the fibrotic cascade is the
migration of PSC to the newly formed basement membrane rich in collagen I and
the penetration, or invasion through the matrix. Our data show a timely increase
in both PSC migration and invasion following stimulation with PGE2. MMP-2 and
MMP-9 degrade the extra cellular matrix thereby facilitating the penetration of the
cells through the basement membrane. Our data also show that PGE2 increases
the expression of MMP-2 and MMP-9 in serum starved PSC. PGE2 mildly
stimulated the proliferation of PSC, however, the role of proliferation in already
activated PSC is debatable. It has been suggested that stellate cells that make
up the fibrotic reaction do not all derive from quiescent stellate cells. Stellate cells
also derive from bone marrow and epithelial mesenchymal transitions(154) .

Until now the specific effects of prostaglandins on PSC has not been
identified. I observed that there are several potential sources of prostaglandins
within the microenvironment of PDAC including PDAC cells as well as PSC
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themselves.

I also found that PGE2 stimulated PSC functions including

migration, proliferation, invasion and expression of genes such as MMPs and
TIMPs which are likely to determine whether fibrosis recedes or procedes (155,
156).
This study also examined the role of PGE2 in apoptosis of PSC. I found
that PGE2 does not stimulate apoptosis of PSC. Furthermore, treatment with
PGE2 caused an increase in cell proliferation. The importance of PSC- PDAC
has recently been the focus of many studies. Recent studies have shown that
PSC promoted the progression of PDAC (157). The co injection of PSC and low
numbers of PDAC cells in a nude mouse model resulted in 100% tumor
incidence, as opposed to 57% when the cancer cells were injected alone.
Although the role of importance of the stroma in PDAC is well known, the
molecular mechanisms that regulate stromal activity and the downstream
signaling involved are poorly understood. This study provides evidence for the
first time that PGE2 can induce major changes in the “fibrogenic response”
associated with PDAC and CP. These changes include contribution to the
formation of the “fibrotic” matrix by changing its composition, migration, invasion
as well as changes in gene expression. Therefore, prostaglandin E2 is
responsible for inducing pro fibrogenic changes in pancreatic stellate cells.
Furthermore, it has been shown that TGF-b secreted by the cancer cells
activates quiescent stellate cells. (158) Candidate genes that mediate tumor
stroma interactions have been identified by gene expression profiling.
Cyclooxygenase-2 (COX-2) was one of the genes that was found to be high in
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both PDAC and CP. Studies have shown the COX-2 pathway to be an important
target in the treatment and prevention of many cancers including pancreatic
cancer (159). A study done has shown COX-2 gene and its primary and most
important metabolite prostaglandin E2 (PGE2) to be expressed in over 90% of
pancreatic (160) suggesting that COX-2 maybe a target for chemoprevention and
treatment of PDAC. Many studies support this theory, however, the limited
success of COX-2 inhibitors in the clinic mainly because of the cardiovascular
and renal side effects (152, 161), urges us to look for a more specific target in the
COX-2 pathway.
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CHAPTER THREE: EP4 RECEPTOR IS REQUIRED FOR PGE2 MEDIATED
PSC HYPERACTIVITY
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INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer related death in
the U.S. Currently no effective treatments for PDAC and the dense desmoplasia
surrounding it exist. The prognosis of PDAC is dismal with a 5 year survival rate
of 5%. The dense desmoplastic reaction around the tumor mass is a major
characteristic of pancreatic cancer. Numerous reports in the literature suggest
that the tumor-stroma interactions in the pancreas contribute to progression and
metastasis. Until now, the focus has been on identifying therapy potentials that
targeting the actual tumor disregarding the importance and contribution of the
stroma. No therapies against pancreatic desmoplasia are available. Numerous
reports had shown that cyclooxygenase-2 (COX-2) was upregulated in the
majority of pancreatic cancer patients (92), this over expression was also
associated with advanced tumour stage and correlates with poor prognosis. In
the pancreas, the fibrotic process is associated with inflammation and high levels
of COX-2 activity. Microarray data from our laboratory identify COX-2 gene as
one of the genes that might play a role in stromal hyperactivation. COX-2 levels
were low in normal pancreas tissue however; COX-2 levels increase in chronic
pancreatitis and increase further more in PDAC samples therefore, suggesting a
role of COX-2 in the fibrotic compartment of PDAC. Treatment with NSAIDs like
62

celecoxib, which block COX-2 activity have shown efficient reduction of
tumorigenicity in vitro. Furthermore, pancreatic cancer patients treated with
selective COX-2 inhibitors have presented significant reduction in tumor size and
increased survival. While many studies confirm the chemopreventive effects of
COX-2 inhibitors, the side effects caused by long term therapy with COX-2
inhibitors

such as cardiovascular and renal events are even clearer (118,

120, 146).
The chemopreventive and anti tumorigenic functions of NSAIDs are due to
their inhibition of prostaglandin synthesis by COX mostly, PGE2. PGE2 has been
reported to the COX-2’s most biologically active product. Most of COX-2
functions have been attributed to PGE2. In humans, four receptors called EP
receptors have been identified as mediators of PGE2 activity. EP1,2,3 and 4 are
localized to the plasma membrane and the binding of PGE2 to each receptor
activates specific downstream signaling pathways (162).
EP1 receptor binds a G-protein which increases intracellular Ca2+ levels
and IP3 levels. EP2 and EP4 receptors are Gs protein–linked that increase cyclic
AMP (cAMP), on the other hand, EP3 receptor is Gi linked and blocks cAMP
increase. Therefore, the effects of PGE2 greatly depend on downstream
signaling that starts with second messenger response (104). Recently, studies
have shown that EP receptors play a role in colon carcinogenesis (163) and in
carcinomas of endometrial, breast, and lung (113, 135, 164).
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Despite of the importance of EP receptors in cancer progression and even
though EP-2 receptor has been identified to be crucial for pancreatic cancer
cells, the role EP receptors in pancreatic desmoplasia or PSC biology has not
been identified. PGE2 modulates a wide array of biological functions essential to
tumor growth, progression and survival (90, 165, 166). Therefore, there is a
strong rationale to understand the mechanisms behind PGE2 functions and the
downstream targets of COX-2/PGE2. Selective COX-2 inhibitors have shown
great promise in treating pancreatic cancer but their adverse side effects are not
suitable for long term use (121, 167) therefore, it is clear that the attention must
shift from focusing on COX-2/PGE2 to targeting more downstream effectors such
as EP receptors as a potential therapeutic target. Based on these findings, I
sought to determine the functional role of EP receptors on the stromal
compartment of pancreatic cancer in vitro by looking at the biology of PSC.
The aim of this study was to identify the functional role of each EP
receptor in mediating PGE2 dependent stimulation of PSC. I examined the
mechanism behind PGE2 stimulation of PSC activity by silencing each receptor
to identify the role each plays in mediating the changes inflicted by PGE2.
Furthermore, I explored blocking EP receptors by treating PSC with specific
antagonists against each receptor and measured changes in migration, invasion
and gene expression. This study uses two different approaches to identify the
functional role of each receptor in PSC biology; siRNA silencing and receptor
antagonism. The results of this study were very promising as blocking only EP4
receptor resulted in a dramatic reduction of PSC activity to a near basal level. In
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this study, I have identified for the first time the receptors that mediate the effects
of PGE2 on pancreatic stellate cells. By siRNA mediated silencing, I have
identified EP4 as the receptor responsible for PGE2 mediated effects on PSCs.
Knowledge of the roles of the specific receptors will aid in the identification of
appropriate targets for therapeutic development against pancreatic fibrosis. Thus,
this study provides a better understanding on regulation of stellate cells by PGE2
and further the role of stellate cells on pancreatic stromal hyper stimulation. This
study also identifies EP4 as a mediator of PGE2 activity that is required for PSC
hyper activation therefore, EP4 could be an alternative potential therapeutic
target to reduce COX-2 mediated fibrosis associated with chronic pancreatitis
and pancreatic cancer.
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MATERIALS & METHODS

Materials
Culture media and fetal bovine serum (FBS) were obtained from Life
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman
Chemicals.

Cell Culture
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth
method from pancreatic adenocarcinoma samples from patients undergoing
surgical resection and were immortalized (68) (Hwang RF, 2008). PSCs were
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in
10% DMEM containing 1% antibiotic. PGE2, EP1 antagonist (cat # SC18220)
and EP2 antagonist (cat # AH 6809) were purchased from Cayman Chemicals
(Ann Arbor, MI). The EP4 antagonist (ONOAE3208) was obtained from
pharmaceuticals (Osaka, Japan).
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ONO

Invasion and Migration assays

For studies of cell invasiveness, BIOCOAT Matrigel invasion chambers (BD
Biosciences, Chicago, IL) were used. Briefly , 2 x 105 cells in 100 ul of serum-free
medium were added to the upper chamber and different concentrations of PGE2
(1–1000 nM) in 0.5% serum containing DMEM were added into the lower
chamber. The cells were allowed to invade the Matrigel for 22 h at 370C in a 5%
CO2 atmosphere. DMEM containing 0.5% serum was used as control. The noninvading cells on the upper surface of the membrane were removed with a cotton
swab and the invading cells on the lower surface of the membrane were fixed
and stained with a Diff-Quick stain kit (BD Biosciences), washed twice with water
and air-dried. Invading cells in three adjacent microscope fields for each
membrane were imaged at 20x magnification. To assess cellular migratory
potential, the protocol described above was used, except that migration
chambers devoid of matrigel was used (BD Biosciences, Chicago, IL).
Experiments were performed at least in triplicate, and the results were shown as
mean ± SD of three independent experiments

Reverse transcription-PCR
Total RNA was isolated from PSC with and without siRNA transfection and the
quality of RNA was tested as mentioned previously. DNAse was used to remove
contaminating genomic DNA and RNA purification. Quality of the RNA was
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confirmed by running on a denaturing gel, and we have observed clear 28S and
18S rRNA bands. A non reverse transcribed control was used to assure that no
genomic DNA was amplified. Primers were designed for human
EP1

(5’

ATCGCTTCGGCCTCCACCTTCTTT

3’)

(3’

3’)

(3’

3’)

(3’

GCCAGCGCCACCAACACCA 5’),
EP2

(5’

CTCGCTGCCGCTGCTGGACTATGG

GCAGGCGAGCACCGAGACAATGAG 5’),
EP3

(5’

GGCGCTGGCGATGAACAACGAG

GGCGCTGGAGATGAACAACGAG 5’),
EP4

(5’

CCGCCCCCAGGTAGCCAGGAG

3’)

(3’TGCGGGAGGACAGCGTTCAGGT 5’),
MMP-2

(5’

CTTCTTGTCGCGGTCGTAGTCCTC3’)

(3’

TGGCGATGGATACCCCCTTGA5’) ,
MMP-9

(5’

GCGCTGGGCTTAGATCATTCCTCA

3’)

(3’

GCAGCGCGGGCCATTGTC 5’) ,
The amplified products were separated on 1.5% agarose gels and visualized by
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which
was used as a loading control for the PCR reactions, were forward 5' ATG ATA
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG
AA 3'.
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Transient transfection of small interfering RNA
PSC was plated on 100-mm dishes and transiently transfected with siRNAssiControl (siRNA ID #4611 Ambion INC Austinm TX) and siEP2 and EP4 (siRNA
IDs # 5732, # 5734, Qiagen, Valencia, CA) at a final concentration of 10 nmol/L
(Dharmacon, Inc.) with Hiperfect transfection reagent (Qiagen, Inc.), and lysates
were prepared for RT-PCR after 72 h.

Statistical analysis

All experiments were conducted in triplicates and carried out on three or more
separate occasions. Data presented are means of the three of more independent
experiments +/- standard error mean (SEM). Statistical analysis was done using
GraphPad Prism (GraphPad Software). Comparisons were made using two-tailed
Student's t test and significant difference was defined as P < 0.05. Data are
shown as mean ± SE.
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RESULTS
Evaluation of EP receptors subtype expression in PSC
There are four potential receptors that mediate PGE2 activity that are known to
bind PGE2 with high affinity, EP1-4. For a preliminary screen of the EP receptor
profile in PSC, a set of novel primers for EP1-4 were designed using
Primerselect software, to amplify fragments of each EP receptor by reverse
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transcription-PCR (RT-PCR; each according to Genbank annotations nm000955, nm-000956, nm-000957, and nm-000958 for EP1-4, respectively. The
expression of EP receptors in PSC cells was determined by RT-PCR using
specific oligonucleotide primers. Each of the four bands in Figure 3.1
corresponds to the expected PCR product sizes. EP1, 2, 3 and 4 are clearly
expressed in PSCs (Figure 3.1).
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Figure 3.1. EP Receptor expression. RT-PCR showing the expression of
EP1,2,3,4 in PSC. All four EP receptor subtypes are expressed in PSC
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EP4 receptor is required for maintaining PSCs migration and invasion
Having shown that all four EP receptors are expressed in PSCs, it was of interest
to determine how silencing of each EP receptor, starting with EP2 and EP4,
affects PSC profibrogenic phenotype. To elucidate the functional role of EP
receptors and the mechanism behind the phenotypic changes in PSC caused by
exogenous PGE2, I silenced each of the EP receptors EP2 and EP4. RT-PCR
shows that cells treated with siEP2 or siEP4 respectively show a reduction in
mRNA levels of EP2 and EP4 respectively compared to the siCONTROL (Figure
3.2.1, Figure 3.2.2). Therefore, siRNA treatment against either EP2 or EP4
receptor is successful in inducing silencing and that the transfection with siRNA
significantly reduced the levels of either EP2 receptor or EP4 receptor on PSC.
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Figure 3.2 EP silencing by siRNA: PSC were transiently transfected with
human siControl and siEP2 (1) or siEP4 (2) using Hiperfect reagent and after 72
hours cells were harvested and RNA was extracted. RT-PCR shows the effects
of silencing EP2 and EP4 receptors in PSC. B-actin served as a control for RTPCR.
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To identify the role of EP receptor signaling in mediating PGE2 actions in
PSC, I investigated the effects of silencing of EP2 and EP4 receptor on PGE2
mediated functions. To examine the effects of independently silencing EP2 and
EP4 receptor, I looked at the migration of PSC. PSC were plated in serum
containing media, one day later, the siRNA complexes specific for EP2, EP4 and
siCONTROL were added to the cells. After a total of 48 hours after silencing,
PSC were trypsinized and counted. 20 000 cells were plated in the top chamber
of the Boyden Chamber migration apparatus in serum free media. Either PGE2
or the vehicle, DMSO were added to the bottom chambers to assay the migratory
potencial of PSC in response to PGE2 after silencing EP2 or EP4. After 22hrs,
cells migrated to the bottom side of the chamber were fixed with methanol and
stained with hematoxylin and number of cells migrated or invaded was counted
on atleast 10 fields looking under the microscope. PSC treated with siRNA
against EP2 receptor did not show significant reduction in the rate of migration
(Figure 3.3.1). The migrated cell number was not significantly different from the
control.

However, PSC treated with siRNA against EP4 receptor showed a

dramatic reduction in PSC migration (82 ± 2.906 N=3 migrated cells per area)
compared to the siCONTROL (166.0 ± 4.359 N=3 migrated cells per field)
(P<0.05) (Figure 3.3.1).

Therefore, EP4 silencing completely blocked the

migratory effects of exogenous PGE2 treatment. Thus, migration of human
pancreatic stellate cells induced by the addition of PGE2 is predominantly
mediated through EP4.
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In order to determine the functional role of EP2 and EP4 receptors on
PSC invasion, a Boyden Chamber apparatus that uses Matrigel as the matrix
was used. PSC were transfected with a scramble siRNA (siCONTROL), siRNA
against EP2 or EP4 receptors as described in the methods section. After a total
of 48 hours, PSC were trypsinized, counted and plated at a rate of 20 000
cells/well in the upper chamber of the modified boyden chamber apparatus. The
bottom wells contained 100nM of PGE2 or DMSO as a control. After 22hrs, the
cells invaded to the bottom side of the chamber were fixed with methanol and
stained with hematoxylin and number of cells migrated or invaded was counted
on at least 10 fields looking under the microscope. Transfection of PSC with
siRNA against EP2 receptor or siCONTROL did not affect PSC invasion (Figure
3.3.2). However, silencing of EP4 receptor greatly reduced PSC cell invasion
through matrigel (41.33 ± 10.41 N=3 invaded cells per field) compared to the
control (118.3 ± 13.02 N=3 invaded cells per field) (P<0.05) (Figure 3.3.2).
Silencing of EP4 receptor but not EP2 receptor reduced both PSC migration and
invasion
These data collectively suggest that the effects of PGE2 on PSC migration and
invasion are mediated by the EP4 receptor and not by EP2 receptors. Silencing
of EP4 receptor reduced both migration and invasion of PSC to a near basal
level.
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Figure 3.3 Effects of EP2 and EP4 silencing on PSC PSC were transfected
with siCONTROL, siEP2 or siEP4 serum starved and plated in the top chamber
of (1) a migration boyden apparatus, (2) invasion apparatus (30 x 103 cells/well).
100nM PGE2 or the control were added to the bottom chambers. Cells were
counted and cell migration (1) and invasion (2) were assessed. *, P<0.05
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Enhanced expression of MMP-2 and MMP-9 is mediated by EP4 receptor
To further examine the functional role of EP2 and EP4 receptors in PSC,
changes in the expression of stromal genes, identified by our microarray data as
genes highly expressed in the stroma of PDAC, were studied. PSC were treated
with siCONTROL, siEP2 and siEP4 separatly, for 48 hours. After a total of 48
hours of siRNA treatment, 100nM PGE2 or DMSO (control) was added to the
cells. PSC were incubated for an additional 24 hours with PGE2 and RNA was
harvested. I compared cDNA from PSC treated with siCONTROL, siEP2 and
siEP4 both treated with PGE2. Results show that PSC treated with siCONTROL
or siEP2 showed no change in gene expression of MMP2 or MMP9. However,
PSC treated with siEP4 had a strong reduction in the mRNA levels of MMP2 and
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MMP9 (Figure 3.4).

Silencing of EP2 did not have a measurable effect on

expression of these genes in the presence or absence of PGE2. These data
generated using siRNA silencing of EP2 and EP4 receptor identify EP4 receptor
as the sole mediator of PGE2 activity in PSC. Furthermore, it presents EP4
receptor as “ the” receptor required by PSC to maintain the PGE2 dependent
profibrogenic phenotype which included increased migration, invasion and gene
expression.
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Figure 3.4 RT-PCR showing the silencing effects of siEP2 and siEP4 on
PSC gene expression. PSC transfected with siRNAs (5nM) showed a significant
reduction in the expression of COL1a1, MMP2 and MMP-9 genes as shown by
RT-PCR using specific oligonucleotide for MMP-2 and MMP-9 respectively. Bactin was used as a loading control
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Treatment of PSC with EP4 antagonist reduces the hyper activation of PSC
To evaluate the role of EP1, EP2 as well as provide further confirmation
for the role of EP4 receptor, specific antagonists for EP1, EP2 and EP4 receptors
were used. PSC were plated in the migration chamber of the Boyden Apparatus
then 10uM of each antagonist was added to the lower chambers 1 hour prior to
PGE2 treatment in serum free media. Treatment of PSC with antagonists for
either EP1 or EP2 receptor did not modify cell migration as seen quantitatively
and qualitatively by DAPI staining (Figure 3.5.1). Treatment of PSC with a
specific antagonist against EP4 receptor show a significant reduction in cell
migration from 239.3 ± 30.99 N=3 cells per field to 12.00 ± 5.292 N=3 cells per
field (P<0.05) . To examine whether EP1 and EP2 receptors affect PSC invasion,
PSC were treated independently with specific antagonists against either EP1,
EP2 receptors. Cell invasion was measured and addition of either antagonist for
EP1 or EP2 did not modify cell invasion, Addition of EP4 antagonist strongly
reduced PSC invasion from 188.0 ± 16.17 N=3 cells per field to a near basal
level with only 20.67 ± 2.333 N=3 cells per field (P<0.05) (Figure 3.5.2). These
results clearly demonstrate by two independent methods that EP4 receptor is
required for PGE2-dependent PSC stimulation. Therefore, blocking stromal EP4
receptor could be of therapeutic value for both chronic pancreatitis and the
desmoplasia associated with PDAC.
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Figure 3.5 Effects of specific antagonists for EP1, EP2 and EP4 on PSC
PSC plated at 70% confluency and allowed to settle overnight. Serum containing
media was replated with serum free media for 24 hours before addition of EP1,
EP2 or EP4 antagonists at a dose of 10uM. 1 hour after the antagonist addition
PGE2 was added to the cells for 24 hours. Cell migration and invasion were
assessed by counting the number of cells that penetrated the migration
membrane (1) or matrigel (2). *, P<0.05
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DISCUSSION

COX-2 over expression in pancreatic tumors is both biologically and
clinically important (42, 46, 53) and the use of selective COX-2 inhibitors have
shown great promises (168, 169). However, because of the long term side
effects associated with COX-2 inhibitors, there is now an urgent need to identify
targets downstream of COX-2 that mediate COX-2 activity in the hopes of
identifying safer and more effective strategies to improve the overall prognosis of
pancreatic cancer patients. Studies have attributed the majority of COX-2 activity
and biological functions to PGE2 (170). Four subtypes of membrane PGE2
receptor have been identified. They are called prostanoid receptors EP1,2,3 and
4. The relative contribution of each of these receptors to key signaling events has
not been fully elucidated. The role of the COX-2/PGE2 pathway in the regulation
of the stroma of PDAC has not been studied. This study provides evidence for
the first time that PGE2 EP receptors play a major role mediating pancreatic
stromal hyperactivation and aims at targeting downstream effectors of COX-2 as
an alternative way to reducing stromal hyperactivation associated with CP and
PDAC while avoiding the unwanted effects of COX-2 inhibitors.

Since there are currently no studies that investigate the role of EP
receptors in the stroma of pancreatic cancer, the first part of this study was to
determine the expression of EP receptors in PSC. I found that all of the EP
receptor subtypes are expressed in PSC.
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The four EP receptors that mediate PGE2 functions have been shown to
control many aspects of cancer such as invasion, migration, and growth (163).
Numerous reports have shown that blocking EP receptors as an alternative way
to blocking COX-2 could prove to be beneficial in the clinic (163). There are no
studies on the role of EP receptors in pancreatic desmoplasia or in PSCs. The
proneoplastic roles of EP2 and EP4 receptors have been reported in several
cancers (103, 110, 112, 117, 130, 134). Therefore, to evaluate the role of each
EP receptor subtype in PSCs, I looked at EP2 and EP4 receptors first.
Using siRNA mediated gene silencing I determined the receptor that
mediates the profibrogenic functions of PSC. The data from this study shows that
transfection of PSC with siEP2 did not show a significant reduction in PSC
migration. On the other hand, silencing of EP4 receptor causes a dramatic drop
in the migratory rate of PSC. Next, I assessed the role of EP2 and EP4 in PSC
invasion. Similarly, silencing of EP2 receptor did not reduce PSC invasion
through matrigel. However, when EP4 was silenced, PSC invasion was reduced
to a near basal level even in the presence of PGE2. I also looked at the
expression of MMP-2 and MMP-9. Silencing of EP4 only and not EP2 receptor
reduced the mRNA gene expression of MMP-2 and MMP-9. Therefore, PGE2
mediated MMP-2 and MMP-9 over expression is EP4 dependent. These results
clearly identify EP4 receptor as required for PSC to be able to migrate, invade
and alter the matrix composition. To examine the role of EP1, EP3 and further
confirm these finding, I treated PSC with specific antagonists against EP1, EP2
and EP4 receptors and found that inhibiting EP4 receptor only diminished PGE2
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stimulation of PSC. EP1 or EP2 antagonists were added to PSC prior to PGE2
treatment, and no changes in PSC migration, invasion or MMP-2/MMP-9
expression was detected. However, treatment of PSC with the EP4 antagonist
greatly reduced migration, invasion and gene expression of PSC. These data
provide for the first time EP4 receptor as a potential target for the regulation of
pancreatic stroma formation that may be useful in treatments of pancreatic
diseases including CP and PDAC.
A study done in lung cancer has reported that PGE2 through EP3 and
EP4 receptor regulate the stromal formation and angiogenesis (171), and that
inhibition of COX-2 and EP3/EP4 receptors results in reduction of the stroma and
of CXCL12/CXCR4 axis important in mediating lung cancer metastasis. In
pancreatic cancer, it has been shown that it is the EP2 receptor that regulates
pancreatic cancer cells (172). PGE2 actions are mediating by its receptors EP14. EP receptors are G-protein coupled receptors that mediate a variety of
biological functions. Four EP receptor subtypes have been identified and are
designated EP1, EP2, EP3, and EP4. EP1 signals via increased Ca2+, which leads
to vasoconstriction. EP3 can also serve to stimulate vasoconstriction and inhibits
the generation of cAMP, whereas EP2 and EP4 are known to mediate
vasorelaxation by stimulating an increase in cAMP levels. A recent interest in
studying the role of EP4 receptor in colon cancer has emerged. EP4 receptor
targeting (117) was found to decrease foci formation, metastasis and tumor
incidence. The role of EP receptors in the regulation of the stroma of PDAC has
not yet been shown. Therefore, this study attempted to determine the role of EP
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receptors in the regulation of PSC. I looked at EP2 and EP4 receptors and
silenced by siRNA each receptor. These results show a strong inhibition of
migration, invasion, MMP-2 and MMP-9 expression when EP4 and not EP2
receptor is silenced. These findings suggest that EP4 receptor pathway tightly
regulates pancreatic stellate cell activity.
Although the role of importance of the stroma in PDAC is well known, the
molecular mechanisms that regulate stromal activity and the downstream
signaling involved are poorly understood. This study provides evidence for the
first time that EP4 receptor can control major changes in the fibrogenic response
associated with PDAC and CP. These changes include contribution to the
formation of the fibrillar matrix, migration, invasion as well as changes in gene
expression. I found that prostaglandin E2 EP4 receptor is responsible for the
PGE2 induced changes in pancreatic stellate cells.

Pancreatic fibrosis

associated with either PDAC or CP is untreatable. Evidence showing that fibrosis
of the pancreas is tightly regulated by EP4 receptor presents it as a potential
target for the prevention of pancreatic fibrosis or as adjuvant treatment
administered along with treatments for PDAC.
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CHAPTER FOUR: PGE2 ACTIVATES MULTIPLE SIGNALING PATHWAYS
AND REGULATES COL1A1 EXPRESSION AND TRANSCRIPTIONAL
ACTIVITY IN PSC
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INTRODUCTION

Pancreatic fibrosis is a characteristic of both chronic pancreatitis and the
dense desmoplastic reaction associated with pancreatic cancer. The cellular and
molecular mechanisms that control pancreatic fibrosis are not fully understood,
mostly because of the lack of in vitro models. In 1998, pancreatic stellate cells
(PSC) were discovered. They are now known to be the cells that produce the
majority of the fibrotic reaction in the pancreas (65).

In normal physiological

conditions, PSC are quiescent and are identified by Vitamin A fat droplets and
positive staining for desmin and GFAP. Upon activation, PSC lose their Vitamin A
droplets and increase their expression of alpha smooth muscle actin (a-SMA).
Activated stellate cells express cytokines, chemokines and cell adhesion
molecules. They also produce large amount of extra cellular matrix (ECM)
components, mostly collagen I (65). Collagen I is the most abundant protein in
the ECM and hyper accumulation is a characteristic of pancreatic fibrosis.
Collagen I is formed by the polymerization of pro-α1(I) chain and pro-α2(I) which
are generated by COL1A1 and COL1A2 genes respectively (173). COL1A1 and
COL2A1 exist in a 2:1 ration. Pro collagen molecules have a distinct triple
stranded rope like structure. Once they are processed outside the cell, Collagen I
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fibrils rearrange into long fibrils that cross link to each other in the ECM, which
gives the tensile strength and hardness to the fibrotic tissue (174). In cancers,
study show that both the cells of the microenvironment and the collagen I matrix
are needed for the tumor to progress. An earlier study done by Ronnov Jessen in
1995 supports the role of collagen in tumor progression and demonstrates the
need for both the stromal cells and the collagen I matrix for a primary breast
cancer cell to progress to a more advanced malignant phenotype (175). Primary
breast cancer cells were plated on a plastic petri dish and compared to the same
primary breast cancer cells that were plated on a collagen matrix with
myofibroblasts. Over a period of two weeks, the primary breast cancers cells that
were plated on a collagen matrix in the presence of stromal cells progressed into
an advanced stage whereas the primary cells plated on a Petri dish retained their
primary structure therefore indicating that in order for a tumor to progress, a
collagen rich matrix is required in addition to the myofibroblasts.

In pancreatic cancer, the content of collagen I is three times higher compared
to the normal pancreas (176, 177). Many studies have tried to understand the
role of collagen I in pancreatic cancer. In this study, they assessed the behavior
of BXPC3 plated on different ECM molecules coated dishes. They found that
BXPC3 plated on laminin or fibronectin coated plates no change in morphology
was noted. However, when BXPC3 cells were placed on a collagen I coated
plate, they became more spread out and aggressive (178). Also, pancreatic
cancer cells plated on a collagen I matrix presented a reduction in E-cadherin,
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enhanced proliferation and migration compared to the cells plated on matrigel.
These results show that collagen I triggers the EMT of pancreatic cancer cells
(179). In the same study, collagen I was also shown to increase the invasion and
metastasis of pancreatic cancer. In vivo and in vitro data from a recent study,
show that collagen I up regulation of MT1-MMP contributes to gemcitabine
resistance of pancreatic cancer (180). The clinical relevance of the collagen I
overproduction was assessed in a study done using human PDAC samples.
Collagen I staining of sections taken from human patients with pancreatic cancer
demonstrates that collagen I levels in patients’ correlates with stage and
prognosis of the disease (181). Collagen I has been well studied in pancreatic
cancer because of the extensive desmoplasia surrounding the tumor. However,
the majority of collagen I comes from PSCs and not the tumor. Since the
molecular regulation of Collagen I gene in PSC is not fully understood, it is
therefore necessary to understand the molecular mechanisms that regulate
Collagen I in PSCs.
In this study, I present novel evidence for the regulation of Collagen I gene
expression and activity by Prostaglandin E2 (PGE2). I show that PGE2
stimulates the gene expression of COL1A1 and that this stimulation is mediated
by EP4 receptor. I also demonstrate for the first time by doing promoter analysis
assay that PGE2 regulates the promoter of COL1A1. Blocking EP4 receptor
reduced the hyperstimulation of COL1A1 therefore, EP4 receptor could be a
therapeutic target for the treatment of pancreatic fibrosis associated with chronic
pancreatitis and pancreatic cancer.
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MATERIALS AND METHODS

Materials
Culture media and fetal bovine serum (FBS) were obtained from Life
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman
Chemicals.

Cell Culture
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth
method from pancreatic adenocarcinoma samples from patients undergoing
surgical resection and were immortalized (68)(Hwang RF, 2008). PSCs were
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in
10% DMEM containing 1% antibiotic. PGE2 was purchased from Cayman
Chemicals (Ann Arbor, MI). EP4 antagonist was obtained from ONO
pharmaceuticals (Japan).

Protein extraction and western blot
For protein extraction, PSC in culture were washed twice with ice-cold PBS.
Modified RIPA buffer, with addition of protease inhibitors (Sigma) and
phosphatase inhibitors (Pierce) was used to lyse the cells. The protein lysate was
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collected by cell scraping. Lysates were sonicated and spun down. Protein
concentration of the supernatant was measured with Bio-Rad reagent. 30-50 µg
of protein was loaded per well of the SDS-PAGE gel. Electrophoresis was
performed and the proteins were transferred onto a nitrocellulose membrane and
immunoblotted. Precision plus dual color protein standards served as a
molecular weight marker. The following antibodies were used: phospho CREB
ser 133 and total CREB (Upstate), phospho-AKT, total AKT (Cell Signaling),
Actin (Abcam). Fluorescent goat anti-rabbit 800 and goat anti-mouse 680 (LiCor)
secondary antibodies were used. The bands were visualized, using Odyssey
scanner and quantified with the manufacturers software.

Reverse transcription-PCR
Total RNA was isolated from PSC with and without siRNA transfection and the
quality of RNA was tested as mentioned previously. DNAse was used to remove
contaminating genomic DNA and RNA purification. Quality of the RNA was
confirmed by running on a denaturing gel, and we have observed clear 28S and
18S rRNA bands. A non reverse transcribed control was used to assure that no
genomic DNA was amplified. Primers were designed for human
Collagen

1A1

(5’

TGTCCACCGAGGCTCCCAGAAC

3’)

(5’

CCCAGGCTCCGGTGTGACTCGTG 3’)
The amplified products were separated on 1.5% agarose gels and visualized by
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which
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was used as a loading control for the PCR reactions, were forward 5' ATG ATA
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG
AA 3'.

Promoter cloning of COL1A1
PCR was done to amplify the full length COL1A1 promoter region using the
following primers forward 5’ CTG CCC ACG GCT AGC CGG CCA GCC GAC 3’
and reverse 5’ GCC GGA GGT CCA CAGA TCT GAA CAT GTC 3’. The PCR
product was then cut using NheI and BglIII enzymes to get the full length
promoter. In order to get ligate the promoter to luciferase, DNA ligase enzyme
was used.

Functional Promoter Analysis of COL1A1
Various lengths of DNA fragments upstream of the initiating ATG codon were
PCR amplified and inserted into luciferase reporter vector pGL3, a promoter
vector (Promega) to analyze the promoter of COL1a1. First, the FL COL1A1
promoter was cut with several restriction enzymes to generate plasmids with
different sizes. StuI was used to cut the FL1853 bp COL1A1 promoter and
generate a 1067 bp which was cut with NheI and AvrII restriction enzymes. The
generated fragment of 868 bp was cut with StuI and EcoRV enzymes which
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resulted in a 564 bp fragment. Cutting the 564 bp fragment with pvuII generated
a 376 bp fragment.

Transient DNA transfection
Transient transfection of luciferase reporter plasmids was performed using
LipofectAMINE (Life Technologies, Inc., Gaithersburg, MD), according to the
protocol recommended by the manufacturer. Briefly, cells were seeded at about
70% confluency in a 24 or 6 tissue culture dish in serum containing media for 24
hours. Then, PSCs were treated with transfection mixtures containing 400 ng and
2ug for 24 and 6 well plates respectively, of luciferase reporter plasmids and 0.5
mg of promoterless as a negative control vector for 7 h at 37°C. Then, 3 ml of
growth media were added to the cells, followed by incubation for an additional 16
h. The cells were then serum starved for 16-18 hours before PGE2 or the vehicle
addition and harvested 72 h after the transfection. As a positive control, PSC
were transfected with GFP-luc vector in the same experimental conditions and
GFP expression was assessed by fluorescent microscope (Olympus).
Luciferase Assays
After a total of 70 hours since transfection the media was replaced with luciferin
containing media. 15ug/ml luciferin in PBS was added to each well and luciferase
activity was assessed by measuring the signal using IVIS machine using the
automatic settings.
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Statistical analysis

All experiments were conducted in triplicates and carried out on three or more
separate occasions. Data presented are means of the three of more independent
experiments +/- standard error mean (SEM). Statistical analysis was done using
Graph Pad Prism (GraphPad Software). Comparisons were made using twotailed Student's t test and significant difference was defined as P < 0.05. Data are
shown as mean ± SE.
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RESULTS

PGE2 regulates CREB levels
PGE2 is reported to increase cAMP levels and activate PKA/CREB signaling
pathway. Furthermore, CREB has been shown to be involved in migration and
metastasis. Therefore, to determine whether the CREB pathway is activated by
PGE2 in PSC, cell lysates treated with several time points of PGE2 were
isolated. Using a specific antibody against phosphorylated CREB (ser 133),
western blot analysis determined that PGE2 increases the phosphorylated levels
of CREB at 10 and 15mins (Figure 4.1). Therefore, suggesting that there might
be EP receptor specificity for mediating PGE2 functions in PSC (162).
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Figure 4.1 PGE2 induces cAMP response element binding protein (CREB)
in PSC (1) Western Blot of phosphor and total CREB at 0,5,10,15,30,45,60 mins
after stimulation with PGE2 in PSC. PGE2 induces phosphorylation of CREB at
ser 133 residue (2) Densitometry analysis of the relative amounts of total CREB
and p-CREB from 3 separate experiments (n=3). Values are the mean and SEM.
*, P<0.05
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Regulation of AKT by PGE2
A number of signaling pathways is reported to regulated cell motility. The
PI3K/AKT pathway has been shown to stimulate invasion, migration, and MMP-2
and MMP-9 expression in many cell types (182, 183). Therefore, the PI3K/AKT
signaling pathway was evaluated following PGE2 treatment. PSC were serum
starved and treated with 100 nMPGE2. The levels of phosphorylated (ser 473)
AKT were determined by western blotting analysis. The levels of phosphorylated
AKT did not change following PGE2 treatment (Figure 4.2).

100

Figure 4.2 PGE2 does not activate Akt pathway in PSC (1) Western Blot of
phospho and total Akt at 0, 5, 10, 15,30,45,60 mins after stimulation with PGE2
in PSC. PGE2 does not induce phosphorylation of Akt
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PGE2 regulates COL1A1 mRNA expression and activity

The majority of pancreatic cancers have high levels of COL1A1 mostly
produced by PSC, which facilitates their invasion and metastatic potential. In
addition, previous data shows that PGE2 stimulates the expression of ECM
molecules in PSC. Therefore, to examine the role of PGE2 in the regulation of
COL1A1 gene expression in PSC, PSC were serum starved for 24 hours before
PGE2 addition, RNA was extracted and RT-PCR was performed on the cDNA
obtained. The results from the RT-PCR demonstrate a strong increase in the
mRNA levels of COL1A1 gene after 24 hours treatment with PGE2 compared to
the negative control treated with DMSO. In the absence of PGE2, serum starved
PSC showed little expression of COL1A1 gene. These results demonstrate that
PGE2 increase COL1A1 gene expression in PSC (Figure 4.3.1).

To further investigate the role of PGE2 in the regulation of COL1A1 gene,
transient transfection of PSC with a construct prepared from the full length
promoter of COL1A1 gene ligated to a luciferase reporter gene was performed
(Figure 4.3.2, 4.3.3). The results of the transfection indicate that treatment with
PGE2 for 7 hours induced a ~2.5 fold increase in transcription (Figure 4.3.2). In
order to evaluate the promoter activity

of COL1A1 gene further, PSC were

transfected with the full length COL1A1 promoter for 24 hours and PGE2 was
added to serum starved PSC for 17 hours. Treatment of PSC with PGE2 for 17
hours showed a steady increase in the promoter activity of COL1A1 which was
not seen in the negative control (Figure 4.3.3). Treatment with DMSO (negative
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control) did not stimulate COL1A1 promoter activity. These results confirmed the
data from the previous time point done at 7 hours that PGE2 treatment causes a
strong induction of COL1A1 promoter luciferase activity.
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* P < 0.05
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Figure 4.3. PGE2 induces the mRNA expression and transcription of
COL1A1. (1) 0 or 100 nM PGE2 was added to PSC after overnight serum
starving and RNA was extracted after 24 hours of treatment. As shown by RTPCR conducted with respective human primers, PGE2 stimulated the expression
of COL1A1. b-actin was used as a loading control.(2),(3) PGE2 induction of the
transcriptional activity of COL1A1. PSC were transiently transfected with pGL3luc-COL1A1 promoter contruct. PGE2 (0, 100nM) was added 7 hours (2) and 17
(3) hours before measuring luciferase activity. Luciferase activity was measured
in photons/seconds using IVIS software. *, P<0.05
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Analysis of the COL1A1 promoter constructs demonstrates that PGE2
regulates several areas in the COL1A1 promoter
To identify the core promoter essential for transcriptional activation, 5’
truncations of the ~1.8kb full length COL1A1 promoter were prepared and
analyzed by luciferase assay (Figure 4.4.1). Various sized constructs ligated to a
luciferase reporter gene were transiently transfected in PSC. PGE2 was added
for 24 hours and luciferase activity was assessed in the presence of PGE2 for
each construct and compared to the full length COL1A1 construct. COL1A1
promoter activity of the 1067 bp, 868 bp, 564 bp and 376 bp constructs were
determined after PGE2 treatment and compared to the full length COL1A1
promoter activity and the promoterless negative control. Data obtained shows
that PGE2 stimulates all four constructs. No statistically significant difference was
noted between the full length COL1A1 promoter and the various sized
constructs. As shown in Figure 4.4.2, transcriptional activity in PSC was not
significantly different between the various truncated fragments compared to the
full length fragment. Minimal change is activity was detected; however the 868 bp
fragment exhibited the minimal activity. Nevertheless, these activities are still
significant because they were several folds the activity of the promoterless
reporter plasmid (negative control). This data suggests PGE2 regulates one or
more areas in the COL1A1 promoter.
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Figure 4.4 Functional analyses of regulatory regions in the COL1A1
promoter responsible for mediating PGE2 activation of transcription. (1)
Schematic representation of the various constructs generated by restriction
enzyme digestion and ligated to a luciferase reporter gene. (2) ) PGE2 induction
of the transcriptional activity of COL1A1 constructs. PSC were transiently
transfected with each of the generated pGL3-luc-COL1A1 promoter contructs
shown in (1). PGE2 (0, 100nM) was added for 17 hours before measuring
luciferase activity. Luciferase activity was measured in photons/seconds using
IVIS software. *, P<0.05
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Inhibition of EP4 receptor reduces COL1A1 expression and activity

PGE2 signaling through EP4 receptor has been associated with
tumorigenesis and I have previously found that PGE2 mediated PSC
hyperactivation is EP4 dependent. I have also shown that blocking EP4 receptor
reduces the profibrogenic phenotype of PSC by decreasing migration, invasion
and MMP-2, MMP-9 expression that accompany high levels of PGE2. Therefore
demonstrating that blocking EP4 receptor could be used as an anti fibrogenic
therapy to reduces PSC activity. To further examine the role of EP4 receptor in
hyper activation of PSC, I evaluated the role of EP4 receptor in mediating PGE2
dependent COL1A1 stimulation. First, to determine whether PGE2 increases
COL1A1 expression via EP4 in PSC, siRNA silencing was performed. siRNA
silencing of EP4 receptor decreased COL1A1 gene expression in PSC treated
with PGE2 compared to the negative control (Figure 4.5.1). To complement the
siRNA approach, a pharmacological approach was used. A selective EP4
antagonist (ONO) was added to serum starved PSC 1 hour prior to PGE2
treatment and total RNA was collected. Using RT-PCR, I found that treatment of
PSC with the antagonist prior to PGE2 blocked PGE2 stimulation of COL1A1
mRNA (Figure 4.5.2). These results suggest that blocking EP4 receptor by either
siRNA silencing or pharmacologically using EP4 antagonism reduces COL1A1
expression.
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To determine the role of EP4 in mediating the transcriptional activation of
COL1A1 by PGE2, PSC were transiently transfected with the full length COL1A1
promoter construct. After 24 hours of serum starvation, PSC were treated with
EP4 antagonist 1 hour prior to addition of PGE2 for 17 hours. Luciferase activity
was measured after a total of 70 hours after the transfection. The increase in
COL1A1 transcriptional activity caused by PGE2 addition was reduced to a near
basal level when EP4 antagonist was added compared to the DMSO treated
negative control. Therefore, EP4 antagonist nullifies the actions of PGE2 hyper
activation of COL1A1 promoter (Figure 4.5.3).

These results demonstrate that EP4 receptor is require for PGE2 to
increase COL1A1 activation and that blocking EP4 receptor by both siRNA and
EP4 antagonist reduces both the expression and the transcriptional activity of
COL1A1 caused by high levels of PGE2.
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Figure 4.5 Effects of blocking EP4 receptor on COL1A1 expression and
transcription (1) PSC transfected with siRNAs (5nM) showed a significant
reduction in the expression of COL1A1 gene as shown by RT-PCR using specific
oligonucleotide for COL1A1. B-actin was used as a loading control. (2) PSC
treated with 10uM of the EP4 antagonist 1 hour prior to PGE2 (100nM) addition
showed a significant reduction in the expression of COL1a1 gene compared to
the control as shown by RT-PCR using specific oligonucleotide for COL1A1. Bactin was used as a loading control. (3) PGE2 induction of the transcriptional
activity of COL1A1 was blocked by EP4 antagonism. PSC were transiently
transfected the full length pGL3-luc-COL1A1 promoter contruct. PGE2 (0,
100nM) was added for 8 hours before measuring luciferase activity. EP4
antagonism reduced PGE2 dependent activation of COL1A1 promoter.
Luciferase activity was measured in photons/seconds using IVIS software. *,
P<0.05
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DISCUSSION

Pancreatic fibrosis is a common feature in chronic pancreatitis and
desmoplasia associated with pancreatic cancer. Pancreatic fibrosis is associated
with inflammation and high levels of COX-2/PGE2 (132) I have previously shown
for the first time that PGE2 promote the fibrogenic response by increasing the
overall activity of PSC. To further understand the molecular mechanisms of
PGE2 mediated pancreatic fibrosis, I looked at the downstream signaling
pathways activated in PSC by PGE2 and at the role of PGE2 in Collagen I
hyperstimulation. Since previous data show a strong for EP4 receptor in
mediating PGE2 hyper activation of PSC functions, I looked at CREB and AKT
pathways known to be activated by EP4 receptor (103). I found that PGE2 does
not activate AKT pathway in PSC. AKT is known to be involved in survival and
evasion of apoptosis. I have previously found that PGE2 does not affect PSC
apoptosis and survival therefore; this data further confirms that PGE2 is not
involved in survival of PSC. I also looked at CREB and found that PGE2 induces
the expression of phosphor CREB (ser 133) in PSC; Therefore, suggesting that
PGE2 could activate the transcriptional potential of CREB. Collagen I is the most
fibrous collagen and about 84% of the collagen synthesized by fibroblast (184).
PSC produce the majority of Collagen I associated with fibrosis (63, 65). In
pancreatic cancer, Collagen I overproduction has been correlated with increased
tumor growth, metastasis, invasion, angiogenesis and EMT (178, 180, 181, 185,
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186). Collagen I has also been found to correlate with poor prognosis and
gemcitabine resistance (180, 181). Therefore, Collagen I is clearly important for
the development and progression of pancreatic cancer. It is known that active
PSC deposit tremendous amounts of Collagen I which serves as a matrix where
the tumor and the stroma communicate by exchanging factors. Studies have
shown that the normal Collagen IV rich basement membrane is slowly replaced
by a fibrotic Collagen I matrix which triggers PSC migration and proliferation in
order to propagate the fibrotic response. Collagen I is needed for the formation of
the fibrotic matrix which serves as an anchorage site for cells and as storage for
cytokines and growth factors that provide signaling clue to the stroma and cancer
cells. However, how Collagen I gene is regulated at the molecular levels is still
not fully understood. Collagen I is composed of two polypeptide chains proα1 and
proα2 in the ratio of 2:1. COL1A1 and COL1A2 genes control the synthesis of the
two chains. Several studies have shown that the over production of Collagen I
during the fibrotic process is largely due to an increase in the transcription rate
(187, 188). The major cytokine reported to regulate the COL1A1 gene which is
more abundant than COL1A2 is TGF-β (189). Numerous efforts have been made
to identify the pathways that regulate the COL1A1 transcription and earlier
studies identified TGF-β responsive sequences in the COL1A1 promoter which
contain binding sites for Sp1, smad and AP1 (188). PGE2 was previously shown
to stimulate PSC activity and alter the extra cellular matrix composition by
increasing the expression of several ECM genes like fibronectin and elastin.
Therefore, in order to further investigate the mechanism of PGE2 mediate PSC
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activation at the molecular levels, I hypothesized that PGE2 stimulates hyper
activation of PSC by increasing COL1A1 expression and transcriptional
activation. The results of this study demonstrate that PGE2 has marked effects
on Collagen I over production, by PSC. First, I show that PGE2 increases the
mRNA expression of COL1A1 gene which is concurrent with the previous data
that show that PGE2 stimulates ECM genes. In order to identify the role of PGE2
in the transcriptional regulation of COL1A1, the full length 1.8 kb promoter was
cloned and ligated to luciferase reporter gene then transiently transfected in
PSC. Luciferase readings show that PGE2 treatment induces the activation of
COL1A1 transcription at several time points. This suggests that COL1A1
promoter might have important regulatory sequences controlled by PGE2.To
perform a functional analysis of the upstream sequences of COL1A1, several
chimeric constructs containing DNA fragments of various sizes were generated
by restriction enzyme digestion. Fragments were ligated to luciferase reporter
gene and their expression was examined after transient DNA transfection of
PSC. Maximum transcriptional activity was noted when the full length promoter
sequence was included. Minimal activity was detected with the transfection of the
868 bp segment. However, the differences were not significantly different and
PGE2 induced the activity of all the segments generated. These results indicate
that PGE2 regulate one or more region of the COL1A1 promoter. It could also
indicate the PGE2 regulates the 376 bp region included in all five constructs.
CREB (cAMP-response-element-binding protein) is a transcription factor that
binds to cAMP-responsive element (CRE) promoter sites to regulate the
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transcription of genes involved in a variety of physiological functions including
cancer and inflammation(190). Previous data show that PGE2 stimulates the
phosphorylation of CREB at ser133. The phosphorylation of CREB at this residue
triggers the relocalization of CREB to the nucleus where it could act as a
transcription factor or activator (190). Analysis of the COL1A1 promoter by TF
search software showed that CREB has four binding sites. The four CREB
binding sites are located within the 376 bp fragment generated by restriction
enzyme digestion. Preliminary data based on siRNA studies show that silencing
of CREB reduces the COL1A1 gene expression (data not shown) therefore,
CREB could be mediating the PGE2 dependent transcriptional activation of
COL1A1 by either being the transcription factor that binds to the 376 bp region or
by being a co-activator. Nevertheless, the goal of this study is to identify the
molecular mechanisms behind PGE2 mediates pancreatic fibrosis by looking at
the mechanisms that govern COL1A1 hyper stimulation and identifying the
transcription factor is beyond the scope of this study. To further investigate the
mechanisms of COL1A1 stimulation by PGE2, I looked at EP4 receptor. Previous
data show that EP4 mediates the majority of PGE2 dependent PSC profibrogenic
activity. Similarly, the results of this study show that blocking EP4 receptor by
either transfecting with siRNA against EP4 receptor or pharmacologically by
using an EP4 antagonist, approved for the use on humans in Japan, reduces
both the expression and the transcriptional activity of COL1A1 gene. Therefore,
this study demonstrates for the first time a PGE2/EP4 dependent mechanism of
COL1A1 regulation that has not been shown previously. TGF-β has been shown
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to regulate COX-2/PGE2 and is the major regulator of COL1A1 transcription;
therefore an argument could arise that the effects of PGE2 on COL1A1 could be
that of TGF-β. However, TGF-β regulation of COL1A1 has been shown to be a
SMAD dependent mechanism that is independent of PGE2. Therefore, blocking
EP4 receptor would not reduce COL1A1 stimulation by PGE2 to a near basal
level if TGF-β was the sole regulator of COL1A1. The reduction of COL1A1
activation observed by blocking EP4 receptor could be potentially used as a
therapeutic approach to reduce fibrosis.
In summary, the data presented in this study indicate an important role for
PGE2 in the regulation of hyper activation of PSC seen in PDAC. As PGE2 is
overproduced by PSC, it could represent an important step in the development of
pancreatic fibrosis during chronic pancreatitis and pancreatic cancer. This study
also identifies EP4 receptor as a possible target for the selective inhibition of
PGE2 dependent COL1A1 hyper stimulation that defines hyper activation of the
stroma.
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CHAPTER FIVE: SUMMARY AND FUTURE DIRECTIONS
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SUMMARY

Pancreatic cancer is one of the most lethal diseases of our times. It is the 4th
leading cause of cancer related death in western countries including the US. Also
called the “silent killer” because of the absence of symptoms in patients,
pancreatic cancer is detected at a late stage when patients already develop
metastases. In rare cases, pancreatic cancer is detected early and is resectable
however; approximately 80% of patients still succumb to his disease and die
within 5 years of resection because of reoccurance and metastasis. Pancreatic
cancer is highly resistant to chemotherapy. Despite the extensive research done
to identify novel therapies for PDAC, gemcitabine is still the first line therapy and
the response rate is very low. Recent emphasis has been on the extensive
desmoplastic reaction that surrounds pancreatic cancer. Pancreatic desmoplasia
has been shown to impede proper drug delivery to the tumor and decrease
survival in mice by acting as a barrier that shields the tumor. Tumor stroma
interactions in pancreatic cancer are highly bidirectional. The stroma produces
high levels of factors that aid tumor progression, such as MMP-2 which increases
angiogenesis of the tumor, and vice versa the tumor produces cytokines and
growth factors such as TGF-β and PDGF which activate the stroma.
Inflammatory molecules such as COX-2/PGE2 have been reported to be high in
both chronic pancreatitis and pancreatic cancer which share a common
denominator; hyper activation of PSC. However, the role of COX-2/PGE2 in
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hyper activation of the stroma is not known. The PSC has been identified as the
major cell that produces the fibrotic reaction. Activation of PSC is followed by an
increase in proliferation, migration, gene expression and collagen I deposition.
Understanding how the stroma is regulated could lead to the identification of
stroma specific targets that can reduce or block desmoplasia which can reduce
chemoresistance, increase pancreatic cancer diagnosis, prevent metastasis,
tumor growth and reduce the tumor burden which will increase patients’ survival.
Therefore, more research to increase the understanding of the pancreatic
stellate cell (PSC) to put us one step closer to finding the cure of pancreatic
cancer and increasing patient lives. The hypothesis of this dissertation was that
PGE2 regulates stromal hyperactivation by amplifying PSC “profibrogenic”
phenotype and COL1A1 activity via EP4 receptor which may be an important
target for the treatment of this pathology.
To address this hypothesis, I first assessed the effects of PGE2 on PSC
biology. Since it is not known whether PSC produce COX-2/PGE2 the first step
was to determine the presence of COX-2 and PGE2 in PSC. I found that COX-2
was over expressed in pancreatic cancer and that PSC express COX-2 mRNA. I
also used liquid chromatography tandem mass spectrometry to quantify the
levels of PGE2 in PSC and found PSC to possess high levels of PGE2 both
intracellular and extracellular. PGE2 levels were the highest among all
ecosanoids profiled. Therefore, the high levels of stromal PGE2 could have an
effect on PSCs. To address this question, I dissected the “fibrotic reaction”
associated with pancreatic cancer based on the literature. Upon activation, PSC
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proliferate which causes an increase in gene expression. Once activated PSC
migrate and penetrate through the membrane while depositing huge amounts of
ECM mostly collagen I which forms a newly fibrotic matrix rich in collagen I. The
collagen I rich matrix replaces the normal basement membrane made of
Collagen IV. Collagen IV degradation by MMPs increases. To determine the
effects of PGE2 on PSC, changes in each step mentioned above was studied
after PGE2 treatment. I found that stimulation of PSC by PGE2 increases all of
the above mentioned steps of the “fibrotic reaction” including migration, invasion,
gene expression of ECM molecules such as fibronectin, elastin, HSPG2 and
others. A panel of MMPs was also evaluated and PGE2 was shown to increase
the mRNA expression of MMP-2, MMP-9 and TIMP-1 specifically. The
proliferation of PSC was stimulated by PGE2. The idea of PGE2 as a
profibrogenic molecule in pancreatic cancer is being explored currently and has
been presented at the recent American Pancreatic Association.
To explore the mechanism behind PGE2 mediated PSC stimulation, I
evaluated the role of each EP receptor subtype in PSC hyper activity in the
second aim of this dissertation. All four receptors were expressed in PSC.
Several reports emphasize the role of EP2 and EP4 in tumor development and
progression therefore, the first part aimed at silencing EP2 and EP4 in PSC and
measuring changes in migration, invasion and looking at the mRNA expression
of MMP-2/MMP-9. I found that silencing only EP4 receptor and not EP2 resulted
in a near complete blocking of PGE2 dependent stimulation of migration,
invasion and gene expression. These results suggest that EP4 is required for
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PSC activity. To assess the role of EP1 and EP3, and to further confirm the
results of the siRNA silencing, I used a pharmacological approach. Specific
chemical antagonists against each EP receptor were obtained. PSC treated with
each antagonist were subjected to migration, invasion assays as well as gene
expression studies. The data from this study confirm that only EP4 receptor is
required for PGE2 to stimulate PSC activity. Blocking EP4 receptor resulted in a
reduction to a near basal level of many of PSC profibrogenic functions such as
migration, invasion and gene expression therefore, identifying EP4 receptor as a
potential therapeutic target for hyper activation of the pancreatic stroma. Blocking
EP4 may reduce the desmoplastic reaction surrounding pancreatic cancer and
help overcome the problem of impeded drug delivery to the tumor caused by
desmoplasia in pancreatic cancer.
The third aim of this dissertation is to identify the molecular mechanism by
which PGE2 regulates PSC by studying COL1A1 gene regulation. I
demonstrated that PGE2 regulates the expression of COL1A1. I also cloned the
COL1A1 full length promoter and ligated it to a luciferase reporter gene to
determine the transcriptional activation of COL1A1 by PGE2. I found that PGE2
induced the promoter activation of COL1A1 in as little as 7 hours. I also did
functional studies to analyze the promoter of COL1A1 by generating various
fragments of the COL1A1 promoter. Analysis of the 5’ truncations of the promoter
revealed that the transcriptional activity of all four truncations increased with
PGE2 treatment. These findings suggest that PGE2 may regulate elements
present in the 376 bp region that is common to all four truncations. Bioinformatics
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analysis of the COL1A1 promoter identified several CREB binding sites in the
COL1A1 promoter particularly in the 376 bp region. Furthermore, PGE2 was
found to increase the phosphorylation of CREB at ser133 which triggers its entry
to the nucleus to act as a transcription factor. Therefore, one possibility could be
that CREB regulates the 376 bp region of COL1A1. However, identifying the
transcription factor that regulates COL1A1 is beyond the scope of this study.
Since blocking EP4 reduced the overall fibrogenic phenotype of PSC, I
explored the role of EP4 receptor in PGE2 mediated COL1A1 activation of
transcription and expression. I demonstrated that EP4 receptor is required for
PGE2 to induce COL1A1 expression and transcriptional activity by both silencing
by siRNA EP receptor and by using a pharmacological antagonist. These results
identify a novel mechanism by which COL1A1 is regulated.
In conclusion, this work demonstrates that PSC produce high levels of PGE2
and that PGE2 regulates the profibrogenic phenotype of PSC by stimulating
migration, invasion, ECM production and degradation. Moreover, blocking each
EP receptor showed that only EP4 receptor is required in PGE2 mediated
stimulation of PSC. Furthermore, this study delineates for the first time that PGE2
regulates the expression and transcriptional activity of COL1A1 via EP4 receptor.
Blocking EP4 receptor results in a complete reduction of PSC activation and
COL1A1 activity therefore, this study identifies EP4 receptor as a potential
therapeutic target for pancreatic fibrosis associated with chronic pancreatitis and
pancreatic cancer.
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FUTURE DIRECTIONS

Will blocking EP4 receptor in PSC reduce desmoplasia and increase
gemcitabine effectiveness in vivo?

In order to show the effect of blocking the production and function of PGE2 on
pancreatic fibrosis by targeting EP4 receptor in vivo studies are needed. A
mouse model of orthotopic implantation of pancreatic cancer (human) with
associated stromal production (mouse) will be used.
Preliminary data from experiments on 14 pancreatic cancer cells, CAPAN- 2
(ATCC) and primary pancreatic cancer cells freshly isolated from pancreatic
cancer patients cultured in our laboratory (MDAPaCa-1) extensively produced
pancreatic cancer associated fibrosis as seen by H & E staining (Figure 5.1).
MDAPaCa-1 cells were further manipulated to express firefly luciferase to be
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used for bioluminescence in vivo imaging. In this study, MDAPaCa-1 would be
used orthotopically to develop pancreatic cancer and its associated fibrosis.
Preliminary data indicate that liposomal delivery of siRNA is capable of
sustaining silencing for 3 days (Figure 5.2).
In this model, the effect of blocking EP4 on PSC will be studied by treating the
mice every 3 days with either with neutral liposome couple siRNA [A]
siCONTROL or with [B] mouse siRNA against EP4 receptor to specifically target
the stroma. A and B will further be divided into two groups each, treated with
Gemcitabine or Saline solution as a negative control. The rationale behind each
treatment will be: Since the cancer formed will be human and the stroma will be
mouse, administering mouse siEP4 will inhibit COX-2 production in the mouse
stroma, thus reducing PGE2 production and hence will the effects on mouse
stromal cells. After confirming that mouse siEP4 administration reduces PSC
activation and the stroma, treatment with gemcitabine would answer the question
whether reduction of the stroma would increase chemosensitivity. Survival, tumor
growth and metastasis would be assessed.
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Figure 5.1 H& E staining of pancreatic tumor showing fibrosis. Primary
pancreatic cancer cell line (MDAPaCa1) isolated from human pancreatic cancer
patients was used to develop orthotopic pancreatic cancer. H & E staining
showed extensive fibrosis formation.

Figure 5.2 Silencing luciferase in vivo by neutral liposome coupled siRNA
against luciferase gene. Panc-1 bearing firefly luciferase was orthotopically
injected in mice and tumor was developed. Neutral liposomes coupled against
siRNA luciferase were injected i.p. and bioluminescence imaging showed
significant silencing at 1-3 days. Luciferase activity was expressed as
photons/seconds.
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How does CREB regulate COL1A1?

Pancreatic cancer is characterized by excessive deposition of Collagen Ia1 by
PSC surrounding the tumor. The increase in stromal Collagen I in pancreatic
cancer has been linked to EMT, survival, invasion and metastasis. Collagen Ia1
deposition by stellate cells is central for the development and progression of
cancer associated fibrosis, however the molecular mechanism leading to the up
regulation of collagen I levels by PSC in pancreatic cancer is unknown. Previous
data show that PGE2 stimulates the production of extra cellular matrix genes via
EP4. Particularly, PGE2 increases the expression of Collagen 1a1. a key
component of the fibrilar matrix formed during pancreatic cancer. Silencing of
PGE2 EP4 receptor only greatly reduces collagen Ia1 expression. Previous
studies also show that PGE2 stimulates the expression of phosphor CREB ser
133. One CREB is phosphorylated at that residue, its transcriptional potential is
activated and CREB enters the nucleus to act as a transcription factor.
Furthermore, analysis of the region upstream of Collagen Ia1 promoter showed
multiple binding sites for CREB (Figure 5.3). Many of the cellular effects caused
by the activation of cAMP/PKA pathway are mediated by the phosphorylation of
CREB on Ser 133. This study would determine the potential role of EP4
mediated cAMP/PKA dependent transcriptional regulation of Collagen Ia1 by
CREB.
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The downstream signaling effectors that mediate PGE2 EP4 receptor up
regulation of Collagen 1 will be determined. cAMP EIA assay will be performed
on PSC with or without PGE2 treatment and siEP4 PSC treated with PGE2. This
assay will be used to determine whether PGE2 activation of EP4 receptor will
result in the activation of cAMP. The agonist Forksolin will be used to determine
whether PGE2 stimulation of Collagen Ia1 will be cAMP dependent by Luciferase
assay on PSC pGL3-E-COL1A1-Luc.L3.6 cell line will be used as a positive
control. To determine whether Collagen Ia1 up regulation by PGE2 is dependent
upon the transcriptional activation of CREB, a mutation of the ser 133 site to
alanine will be done and Collagen Ia1 promoter luciferase assay would determine
if CREB might transcriptionally regulate Collagen Ia1. Promoter analysis using
restriction enzyme digestion of collagen 1a1 would be used to identify potential
binding region for CREB that are PGE2/EP4 dependent. Point mutation in the
CREB binding region of collagen 1 promoter would identify the precise CREB
binding site that could be activated by PGE2. EMSA and ChIP assay will
determine the direct binding of CREB to the site that will be identified as the
CREB binding site of the Collagen Ia1 promoter that will be caused by PGE2
treatment and that will be EP4 dependent.
Mutant construct for CREB binding domains would identify a binding site for
CREB in the promoter region of Collagen Ia1 that would be activated by PGE2
and EP4 dependent.
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Figure 5.3 Bioinformatics analysis of COL1A1 promoter identifies four
putative binding sites for CREB.
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